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SUMMARY
Force development in cardiac and vascular muscle is 
directly related to the concentration of calcium ions in the 
cytosol. Sustained hypertension is predominantly maintained 
by an increase in total peripheral resistance and attention 
has therefore focused on the possibility that changes in 
intracellular calcium in myocytes of resistance vessels are 
important in the pathogenesis of essential hypertension in 
- man. Apart from vascular tone, free calcium in cells also 
stimulates cell proliferation and growth and increased con­
centrations of calcium ions in cardiac and vascular smooth 
muscle could mediate the hypertrophy that characteristically 
occurs in response to an increase in wall tension.
Studies of cytosolic free calcium concentrations in 
vascular smooth muscle cells have not yet been performed in 
man. Instead, blood platelets, which are accessible cells 
that have a calcium-dependent contractile apparatus and a 
complement of membrane receptors not unlike those in vascular 
smooth muscle, have been used to study cellular calcium 
handling. It has been proposed that membrane control of 
intracellular free calcium is abnormal in hypertension, and 
that this abnormality is not limited to the contractile cells 
of the cardiovascular system. This hypothesis has generated a 
considerable volume of experimental work which has extended 
to studies of extracellular calcium metabolism and the 
possible therapeutic role of dietary calcium manipulation.
A high prevalence of hypertension has been described in 
patients with primary hyperparathyroidism, a disease that is
17
characterised by increased parathyroid hormone concentrations 
and chronic extracellular hypercalcaemia.
Tw:. related studies have been carried out to determine 
levels of free calcium in platelets and the relationship of 
these levels to arterial pressures in patients with essential 
hypertension, primary hyperparathyroidism and normal control 
subjects.
The first study examined resting and stimulated free 
calcium concentrations in platelets loaded with the 
fluorescent probe Quin 2 from 30 patients with essential 
hypertension and from 30 age-matched controls. The median 
cytosolic free calcium in platelets in the hypertensive group 
was 93.3 nmol/1 and values were not significantly different 
from those in the control group (87.8 nmol/1, 95% Cl - 1 2 to
5.8, P=0.5). Arginine vasopressin caused a transient increase 
in platelet free calcium in all subjects. In the presence of 
1 mmol / 1 extracellular calcium the increase was significantly 
higher in the control subjects than in the hypertensive 
patients (P=0.005). In the absence of extracellular calcium, 
arginine vasopressin caused much smaller increases and there 
was then no difference between the responses of the two 
groups. Platelet free calcium concentrations were measured 
again in 1 3 patients after 8 weeks of treatment with either 
verapamil (n=6) or atenolol (n=7). The reductions in systolic 
pressure after drug treatment were correlated with the 
changes in cytosolic free calcium concentrations (r=0.75,
p<0.01 ) .
Compared with results of previous studies in essential 
hypertension, the differences in platelet calcium were quite
18
small. The lack of adequate matching for age and body weight 
as well as inclusion of patients with malignant hypertension 
in early reports may account for some of the differences. 
Since an increase in free calcium concentration is a 
necessary part of the process of activation, the higher 
platelet calcium concentrations in some studies may reflect 
changes that occurred after blood sampling as a result of an 
enhanced tendency to activation and aggregation. The rise in 
cell calcium after arginine vasopressin appeared to be 
primarily dependent on calcium influx and this response was 
reduced in the hypertensive group.
The second study examined blood pressure, left 
ventricular mass, platelet cytosolic free calcium, renin- 
angiotensin system, catecholamines and atrial natriuretic 
peptide in 23 patients with untreated primary hyperpara­
thyroidism, 30 normotensive control subjects and 23 control 
subjects matched for age, sex and blood pressure. In 12 
patients measurements were repeated after parathyroidectomy.
Patients with primary hyperparathyroidism had sig­
nificantly elevated blood pressures compared with age-matched 
control subjects and 22% were hypertensive (WHO grades I and 
II). Blood pressures were little changed six to twelve months 
after correction of the hyperparathyroidism by. surgery. 
Despite chronic extracellular hypercalcaemia, intracellular 
free calcium concentrations were lower in patients with 
hyperparathyroidism than in controls matched for age, sex and 
blood pressure (median concentrations 81.5 nmol/1 vs 93 
nmol/1, 95% Cl 0.1 to 20.1; P<0.05) and values tended to
increase after parathyroidectomy. There was an inverse
19
correlation between platelet calcium and diastolic blood 
pressure in the hyperparathyroid group (r=-0.46, P<0.05). The 
median peak concentrations of calcium after vasopressin were 
lower in the hyperparathyroid group than in the control 
subjects (95% Cl 76 to 1551, P<0.001 ). Chronic hypercalcaemia 
or parathyroid hormone excess may lower intracellular calcium 
in some tissues, either by stabilizing the membrane and 
reducing calcium influx or by increasing cyclic AMP.
Left ventricular mass index was increased in the hyper­
parathyroid group as compared to control subjects matched for 
age, sex and blood pressure (123 g/m^ vs 100 g/m^, 95% Cl -
36.1 to -3.1, P=0.03). Parathyroidectomy was associated with
a small reduction of the left ventricular mass index (123.5 
g/m^ vs 104 g / m ^ ,  95% Cl -46.5 to 2.5; P = 0.1). There was some 
evidence that the degree of left ventricular hypertrophy was 
out of proportion to the blood pressure suggesting that 
extracellular calcium or parathyroid hormone may have direct 
effect on cardiac myocytes. The plasma concentrations of the 
components of the renin-angiotensin system, catecholamines 
and atrial natriuretic peptide were similar in patients with 
hyperparathyroidism and the two control groups and apart from 
small changes in aldosterone, they were not affected by 
parathyroid surgery. There was little evidence to implicate 
either the renin-angiotensin or the sympathetic nervous sys­
tems in the pathogenesis of the high blood pressure.
The increased cardiovascular mortality that has been 
described in primary hyperparathyroidism may result from 
hypertension and left ventricular hypertrophy. Further 
prospective studies are required to establish whether cardio-
20
vascular mortality is prevented by parathyroidectomy.
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CHAPTER 1 - REVIEW
"A small quantity of calcium added to saline solution 
with small amounts of potassium chloride, makes a good 
artificial circulating fluid and the ventricle will continue 
beating perfectly for more than four hours". [Sidney Ringer, 
1883 (1 ) ].
The importance of calcium ions to the function of vas­
cular muscle and nerves has been recognised since the time of 
Ringer. Over the past 20 years there has been increasing 
interest in the role of calcium in the pathogenesis of hyper­
tension. Arterial pressure is determined by cardiac output 
and peripheral resistance: calcium ions affect both com­
ponents (2). Calcium directly affects cardiac' output and 
peripheral vascular resistance by stimulating muscle con­
traction and changing responsiveness to and release of vaso­
active substances. Force development in cardiac and vascular 
muscle is directly related to the concentration of calcium 
ions in the cytosol (3). Sustained hypertension is pre­
dominantly maintained by an increase in total peripheral 
resistance and attention has therefore focused on the 
possibility that changes in intracellular calcium in myocytes 
of resistance vessels are important in the pathogenesis of 
essential hypertension in man.
Section 1 - Evidence for and against calcium deficiency in 
genetic hypertension
It may seem paradoxical that so much consideration has 
been given to the possibility that genetic hypertension is
22
associated with calcium deficiency. This section examines the 
evidence.
1.1.1. Epidemiology
The first suggestion that there might be a link between 
calcium deficiency and high blood pressure came from clinical 
studies of essential hypertension (5,6). This was followed by 
evidence of an inverse relationship between calcium intake 
and blood pressure in a population study (4). Paradoxically, 
it had also been found that the concentration of total cal­
cium in serum was positively correlated with blood pressure 
(7) but the relationship has not been evident in all studies 
(8,9). Interpretation of such studies can be difficult and 
this was apparent when two independent groups of 
investigators (4,10) drew different conclusions from their 
analyses of the same data, from the first National Health and 
Nutrition Examination Survey (1971-1973).
Epidemiological surveys of diet are notoriously 
difficult to perform. The method of dietary recall by 
questionnaires is often inaccurate. In relation to hyper­
tension, factors that affect preference for or avoidance of 
dietary products may -independently affect blood pressure. In 
some surveys, possible differences in other nutrients and 
elements like potassium were not completely excluded (4). 
Epidemiologic studies can only document an association but do 
not establish causality.
1 .1 .2 . Increased urinary calcium excretion
There is a general agreement that some patients with 
essential hypertension have increased rates of calcium ex­
23
cretion or hypercalciuria relative to sodium excretion 
(5,7,9,11,12). Similar findings have been described in 
spontaneously hypertensive rats ( SHR) (1 3 ,1 4 ). The renal 
excretion of calcium and sodium is linked and dietary intake 
of sodium is a factor which influences calcium excretion 
(15). Some studies in the SHR have concluded that an 
intestinal mechanism' is responsible for the hypercalciuria 
present in this animal model (16), but such increased 
absorption of calcium is not firmly established (17).
1 .1 .3. Reduced serum ionized calcium
Serum concentrations of ionized calcium have been found 
to be reduced in hypertensive subjects ( 6 ,8 ,9,1 8 ) and SHR 
(13) but these differences have not been confirmed by later 
studies (5,12,19). Confounding variables like pH and food 
intake were not always controlled in the earlier studies 
(1 2,16 ). Resnick et al (18) has examined serum ionized 
calcium concentrations in hypertensives subdivided into low- 
renin, normal-renin, and high-renin subgroups. Low-renin 
patients seemed to show lower levels of serum ionized calcium 
than normal-renin and high-renin groups.. Hypertensive 
patients with high values of plasma renin activity had higher 
serum levels of ionized calcium.
1.1.4. Calcium regulating hormones in essential hyper­
tension
Serum parathyroid hormone concentrations are probably 
slightly increased in middle aged subjects with established 
hypertension (5,11). Concentrations of intact parathyroid 
hormone also seem to be raised in young subjects with mildly
24
raised blood pressure and correlate with the level of 
pressure (20). These observations have generated the hypo­
thesis that enhanced parathyroid gland activity is implicated 
in the development of essential hypertension. Intact para­
thyroid hormone concentration is probably a more sensitive 
index of activity of the parathyroid gland than total 
immunoreactive parathyroid hormone concentration and un­
affected by changes in renal clearance of the metabolites of 
parathyroid hormone which may be present in chronic hyper­
tension (2 1 ).
Increased activity of the parathyroid gland may be an 
appropriate response to a renal calcium 'leak' or to a low 
dietary intake of calcium: both have been reported in
subjects with hypertension (4,5,11). Parathyroid gland 
secretion may be affected by the slight reduction of serum 
ionized calcium concentrations which has been found in gene­
tic hypertension in animals. Parathyroid activity may also be 
influenced by the sympathetic nervous system (2 2 ) and in­
creased sympathetic tone may be present in early essential 
hypertension (23).
The two other calcium regulating hormones calcitonin and 
1,25-dihydroxyvitamin have not been studied as extensively 
as parathyroid hormone. One study from New York-(24) des­
cribed abnormalities in calcium regulating hormones linked to 
renin-sodium status and consistent with the observed 
differences in ionized calcium levels. Calcitonin levels in 
plasma were higher in hypertensive subjects with high renin 
activity than in low-renin and normal-renin groups of normo- 
tensive controls but levels of 1,25-dihydroxyvitamin and 
parathyroid hormone were higher in the low-renin group. There
25
was a significant inverse relationship between circulating 
1,25 vitamin levels and plasma renin activity and a direct 
relationship between calcitonin levels and plasma renin 
activity.
Most of these correlations depend on inclusion of 
patients with high-renin essential hypertension. In Scottish 
experience and except" for patients with renovascular disease, 
high plasma renin concentrations are unusual in essential 
hypertension, occurring only in young patients with severe 
disease (1 2 ).
1 .1.5. Decreased intestinal calcium absorption
In vivo perfusion studies across small intestinal 
segments of the anaesthetised SHR and experiments using 
isolated, everted duodenal sacs have described decreased 
calcium absorption in the hypertensive animals (17). Contrary 
results have also been reported (25) and in situ duodenal 
^Ca uptake in conscious SHR has even been found to be 
greater than in Wistar-Kyoto (WKY) control animals (16). Most 
findings are not compatible with the notion of calcium mal­
absorption in the SHR.
1 .1 .6 . Oral calcium supplementation - conflicting findings
McCarron and Morris (27) reported that one gram of 
elemental calcium caused a small but significant fall in 
blood pressure in hypertensive patients after eight weeks of 
treatment. In normotensive subjects oral calcium 
supplementation also seemed to cause a small fall in blood 
pressure (26,28). Studies in hypertensive rats have shown 
that a large increase in calcium intake does lower blood
26
pressure (14,30,31) but this effect is abolished when 
reductions in phosphate balance are prevented (32), which 
tends to suggest that reduced phosphate is more important 
than increased calcium. Direct effects of phosphate 
deficiency on vascular resistance have been described (33). A 
large retrospective study of blood pressure in hyperpara­
thyroidism failed to show any correlation between blood 
pressure and serum calcium concentration, but did show a 
significant inverse relation with serum phosphate concen­
tration (34).
More recent carefully controlled studies by Capuccio et 
al (29) and Siani et al (35) have not confirmed earlier 
results of McCarron and Morris. Both studies found that 
increases in calcium intake for four weeks in mild to 
moderate essential hypertension did not lower blood pressure. 
Studies on calcium supplementation in hypertension are at 
present inconclusive and there is not yet enough evidence to 
justify a recommendation for calcium supplementation as a 
mode of treatment.
1 .1 .7. Hypertensive effects of acute hypercalcaemia
It is well established that acute hypercalcaemia 
increases arterial blood pressure in man and in experimental 
animals (36-39). Since calcium ions have been shown to 
increase cardiac muscle contractility i_n vitro (40) and 
vascular smooth muscle contraction (41), it has been 
suggested that the hypertensive response is mediated by a 
combination of increased cardiac output and increased 
peripheral resistance. In vivo studies have established that
27
there may be an increase in cardiac output in the initial 
phase of acute hypercalcaemia (42) but the hypertension is 
then maintained by an increase in vascular resistance 
(38,39). Berl et al (39) studied hypercalcaemia in the 
conscious rat achieved by a 30 minute infusion of calcium 
chloride. This resulted in increased mean arterial pressure 
and peripheral vascular resistance (measured using micro­
spheres) but no change in cardiac index. The pressor response 
to acute hypercalcaemia did not seem to be mediated by 
vasopressor hormones or attenuated by vasodepressor hormones 
since inhibition of the renin-angiotensin system, 
catecholamines, vasopressin, prostaglandins and parathyroid 
hormone did not alter the pressor response to calcium. It 
seems likely that there is a direct action of calcium ions on 
smooth muscle and perhaps cardiac muscle, since pretreatment 
with the calcium channel blockers verapamil and nifedipine 
blocks the pressor response (39).
1 .1 .8 Chronic hypercalcaemia
In 1 958 Hellstrom et al (43) reported an increased 
incidence of hypertension in patients with primary hyperpara­
thyroidism and subsequent studies have mostly confirmed this 
observation (34,44,45). Initially it was suspected that renal 
damage caused by hypercalcaemia explained this association 
and renal damage probably does contribute to hypertension in 
some severe cases. But differences in pressure were still 
present when patients with creatinine values of 150 jimol/1 or 
more were excluded (44). Blood pressure elevation may be 
caused directly either by hypercalcaemia or by parathyroid 
hormone excess. Blum et al have described reversible hyper­
tension caused by the hypercalcaemia of hyperparathyroidism, 
vitamin D toxicity and calcium infusion (46). Hypertension 
associated with hypercalcaemia of malignancy has also been 
described (47).
The common occurrence of hypertension in hyperpara­
thyroidism is probably not the explanation for the 
association of hypercalcaemia with high blood pressure in 
epidemiological studies. Bulpitt et al (48) found a positive 
correlation between total serum calcium concentration and 
systolic blood pressure in the Whitehall study and this link 
between blood pressure and calcium is supported by Kesteloot 
and Geboers (7), who showed an independent and highly 
positive correlation between serum calcium concentrations and 
both systolic and diastolic pressure in Belgian soldiers. 
Diuretic treatment was not recorded, but the Renfrew study 
(49) has supported the relation between.calcium and blood 
pressure in a population who were not taking these drugs.
Overall, epidemiological, clinical and experimental 
studies do not provide a firm evidence for the presence of 
calcium deficiency in all forms of genetic hypertension. 
Variables such as age, sex, race or renin-sodium profile may 
contribute to conflicting results obtained by different 
authors. The calcium deficiency hypothesis requires careful 
testing with intervention studies of adequate size and 
duration before calcium supplementation can be regarded as 
adequate therapy for hypertensive patients.
It is agreed that extracellular and intracellular 
calcium homeostasis is abnormal in the spontaneously hyper­
tensive rat and probably also in essential hypertension in
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man. To further understand how these abnormalities might be 
translated to increased peripheral vascular resistance it is 
necessary to consider the mechanisms that regulate the intra­
cellular calcium concentration.
Section 2 - Regulation of the intracellular calcium con­
centration
1.2.1. Calcium and the contractile proteins
The concentration of calcium ions in vascular smooth 
muscle cells is the major determinant of contractile activity 
and free cytosolic calcium is sometimes referred to as 
"activator calcium" (41). Electron microscopy reveals that 
the contractile mechanism of vascular smooth muscle is 
composed of thick (14.5 nm) and thin (6.4 nm) filaments. 
Shortening and force generation is produced in a manner 
similar but not identical to the classic sliding filament 
model of skeletal muscles (50). Filaments do not change in 
length but slide in parallel alignment so that the length of 
the cells tends to shorten. As in skeletal muscle, the thin 
filament consists of the proteins actin and tropomyosin, 
whereas the thick filament consists of myosin. In both types 
of muscle force develops as a result of a cycling motion of a 
bridge extending from the myosin molecule that alternately 
attaches to and detaches from the actin molecule (51).
Cycling or activation of the myosin bridge occurs when a 
light chain of the myos-in molecule is phosphorylated by the 
enzyme myosin light chain kinase (MLCK). There is an 
invariable relationship between myosin light chain phos­
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phorylation and the mechanical response (54). Calcium 
activates MLCK in the presence of calmodulin, and is thus the 
physiological activator of smooth muscle contraction (53). 
Using aequorin to monitor intracellular calcium concen­
tration, Rembold and Murphy (54) have demonstrated the 
relationship between intracellular calcium concentration, 
myosin light chain phosphorylation, and cross bridge cycling 
rate. These investigators have provided a full understanding 
of the mechanism of contraction of vascular smooth muscle and 
have made it clear that this contraction is regulated by the 
concentration of calcium in the myoplasm.
1.2.2. Cellular calcium pools, calcium channels, pumps and 
exchangers
A simple generalised representation of cellular Ca^+ 
compartmentalisation and flux systems is given in Figure 1 . 
The processes that regulate the concentration of the 
activator calcium in vascular smooth muscle cells include 
mechanisms that affect the movement of calcium across the 
plasma membrane and mechanisms that sequester and release 
calcium from the sacroplasmic reticulum (51,52,55). As early 
as 1963, Bohr found it possible to differentiate contractile 
responses to calcium from these two sources (57) after 
observing that the response of the rabbit aorta was comprised 
of a fast and slow component. The early fast component 
depended on intracellular calcium release, and therefore 
could occur in the absence of external calcium; the sub­
sequent slow component depended on calcium influx through the 
membrane (57,58).
Calcium for the fast component of the contraction is
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released from the sacroplasmic reticulum when a constrictor 
agonist activates its specific receptors in the plasma 
membrane. Somlyo and Somlyo have named this process pharmaco- 
mechanical coupling (59). It can occur without a change in 
membrane potential. The role of an intracellular source of 
calcium in response to physiological agonist is demonstrated 
by the observation that vascular smooth muscle contracts when 
stimulated with noradrenaline in a calcium-free medium (58). 
The signal for calcium release is transmitted to the sacro­
plasmic reticulum either by calcium-induced calcium release 
(60) or by inositol trisphosphate (61).
Insight has been gained into the role played by the 
plasma membrane in the regulation of intracellular calcium 
concentration, role that is largely dependent on permeability 
to calcium which in turn is governed by the status of 
specific protein channels in the lipid bilayer. Current con­
cepts of the entrance of calcium into the cell depict it as 
occurring through four different types of channels 
(52,55,56). This classification of the channels is based on 
the specificity of both their mechanisms of activation and 
the actions of various calcium entry blockers (55,62). 1 ) One 
type of channel referred to as the "calcium leak channel" 
appears to be present in all types of biological membranes 
composed of phospholipids, cholesterol and protein. It is 
active in the absence of membrane stimulation. 2) A potential 
sensitive channel becomes increasingly available to the cal­
cium ion when membranes are depolarised. 3) A third type of 
channel is activated when agonists (eg angiotensin II or 
vasopressin) react with their membrane receptor, the so-
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called receptor-operated channel. This channel has a specific 
role in activating the phosphoinositide system. 4) It is now 
apparent that a fourth type of calcium channel may be 
activated by the stretch of vascular smooth muscle (63).
Van Breemen et al (55) have compared the rates of cal­
cium influx in vascular smooth muscle from resistance vessels 
of WKY and SHR through three of these channels. Through the 
leak channel, the receptor-operated channel, and the 
potential-sensitive channel, the influx was greater in smooth 
muscle from the SHR than it was in that from the WKY. More 
detailed characterisation of the calcium channels of vascular 
smooth muscle has been possible with the use of the patch- 
clamp, technique. Rusch and Hermsmeyer (64) have compared the 
whole cell calcium currents of smooth muscle from the azygos 
veins of WKY and SHR. They noted that in both types of cells 
two categories of currents were observed: one transient and 
one long-lasting. Although the total calcium current did not 
differ between the cells from these two sources, the relative 
proportion of transient and long-lasting calcium currents was 
significantly different between WKY and SHR cells. The tran­
sient current was greater in WKY cells, whereas the long- 
lasting current was greater in cells from SHR. Since the 
long-lasting current delivers the calcium, which is thought 
to regulate contraction, it is possible that these 
differences between neonatal animals of the two strains 
account for the difference in peripheral resistance".
Cellular calcium homeostasis is a remarkable achievement 
in that a 5000 fold to 1 0000 fold concentration gradient is 
maintained across the plasma membrane (65). The concentration
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of ionized calcium in the cell cytosol is normally between 
100 to 200 nM and in the extracellular fluid about 1 mM. This 
gradient is maintained by a low natural permeability of the 
plasma membrane to calcium and by at least two ATP-dependent 
mechanisms by which calcium is pumped out of the cell. The 
first is Ca^+/Mg^+-ATPase (6 6 ) and the second is Na+/Ca^+ 
exchanger which is driven by the sodium gradient across the 
membrane, then maintained by Na+/K+-ATPase (67). In general, 
the Na+/Ca^+ exchange mechanism is a high-capacity, low- 
affinity system, which can move relatively large quantities 
- of calcium out of the cell per unit of time. In contrast, 
Ca^ + /Mg^ + -ATPase is a high-affinity, low-capacity system, 
which- fine-tunes the intracellular calcium concentration 
(67). Both are regulated by changes of calcium ions concen­
tration in the cell. When the calcium concentration rises, 
the efficiency of both efflux pathways increases.
The existence of a sodium/calcium exchanger in vascular 
smooth muscle has not been universally accepted. Using 
electrophysiological technique, Hermsmyer and Harder (6 8 ) 
were unable to find evidence of a Na/Ca exchanger in basilar 
and caudal arteries from stroke prone spontaneously hyper­
tensive rats (SHRSP) and normotensive WKY rats. In contrast, 
Matlib et al (69) have observed that calcium uptake by sarco- 
lemmal vesicles of mesenteric arteries from SHR and WKY is 
dependent upon sodium loading. The activity of the exchanger 
appeared slightly greater in membrane vesicles from SHR, but 
the difference was not statistically significant. A review of 
the exchanger in genetic hypertension (70) concluded that 
despite the strong possibility that blood vessels do possess
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a Na+/Ca^+ exchange mechanism, and the attractiveness of this 
exchange as a mechanism linking sodium with the increase of 
vascular resistance, there was little direct evidence for a 
pathogenetic role.
In contrast, significant abnormalities of Ca^+-ATPase or 
calcium extrusion pump have been described in hypertension. 
Kwan et al (71) compared the ATP-dependent calcium 
accumulation into inside-out sarcolemmal vesicles from 
mesenteric arteries of normotensive and hypertensive rats. 
This measure of active calcium extrusion was reduced in both 
SHR and mineralocorticoid-induced hypertension. Postnov and 
Orlov (76), in support of their hypothesis that the membrane 
abnormality in hypertension is generalised to all tissues, 
presented evidence that the calcium uptake by plasma membrane 
vesicles from rat brain is 40% less in SHR than WKY.
The other organelles of central importance to calcium 
homeostasis are mitochondria. An efficient calcium pump 
drives Ca^+ out of the cytosol into the mitochondrial matrix, 
where calcium is stored largely in non-ionic calcium-phos- 
phate complex (65). There is also a calcium leak or efflux 
pathway whereby calcium can leave the mitochondria and return 
to the cytosol. In times of excessive .cellular calcium 
uptake, the rate of mitochondrial uptake becomes much greater 
than the rate of efflux, and the organelles then accumulate 
calcium which protects the cell against overload or 
intoxication (65).
1.2.3. Calcium and the plasma membrane
Not only is the plasma membrane equipped with mechanisms
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that regulate intracellular concentrations of calcium ions, 
but the function of the membrane is itself regulated by- 
calcium. The intracellular environment is protected from 
calcium overload by a mechanism whereby extracellular calcium 
concentration affects cell membrane permeability to calcium 
(52,62). This inactivation of calcium channels by increasing 
concentrations of calcium can be demonstrated by the 
relaxation of vascular smooth muscle that occurs when 
extracellular calcium concentration is increased above 
physiological levels (72). The decrease in membrane 
permeability caused by the increase in calcium concentration 
has been described as "membrane stabilization". It is a 
generalised effect which alters sodium and potassium fluxes 
in lymphocytes (73) and vascular smooth muscle cells (74) in 
genetic and mineralocorticoid hypertension (Figure 2).
At any calcium concentration, the flux is greater 
through the membranes from hypertensive rats than through 
membranes from normotensive rats. This has been interpreted 
as evidence that calcium has less of a stabilizing influence 
in the membrane from the hypertensive rat (62,73). This 
interpretation is in accord with observations that less cal­
cium is bound to isolated cell membranes from genetically 
hypertensive than from normotensive rats or humans (75,76). 
At a molecular level, Kowarski et al (77) found a significant 
reduction of an "integral membrane calcium-binding protein" 
(IMCAL) in various tissues of the SHR as compared to those 
from WKY. It has been suggested that the impaired ability of 
calcium to stabilize the membrane might be a consequence of 
the deficiency of calcium binding sites in the membrane in
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Figure 2 Effects of varying external calcium concentrations 
on net potassium efflux
(a) Lymphocytes from WKY ( □ ) ,  SHR (tZ2) and SHRSP ( ■ ) .  
Bars, means + SEM; from reference 73 by permission.
(b) Aortic smooth muscle from DOCA hypertensive (fE2) and 
hormotensive ( □ )  rats; data reported in tabular form, 
in reference m.
Efflux values from both tissues decrease with increasing 
calcium concentrations. The magnitude of this stabilising 
effect of calcium is less in aortic smooth muscle from DOCA- 
hypertensive rats and in lymphocytes from SHR and SHRSP 
compared to normotensive controls.
hypertension (62,75,76). This unifying hypothesis has been 
outlined by Bohr and Webb (62) in a recent review and is 
summarised in Figure 3.
1.2.4. Calcium as a second messenger
Intracellular calcium serves as a second messenger for 
the control of a variety of cell functions, including 
secretion, contraction, cell division and differentiation, 
and potassium and sodium permeability (78). Although it has 
been assumed for some time that Ca^+ stabilized the plasma 
membrane, the key Ca^+ pool in terms of contractile function 
is the small pool of free Ca^+ in the cell cytosol, [Ca^+ ]i. 
The concentration of Ca^+ in this pool rises during con­
tractile response, and the fall precedes the relaxation 
process (79). Moreover it has recently become apparent that 
this messenger or coupling function of Ca^+ is not confined 
to excitable tissues, but is a universal one. Ca^+ serves as 
a second messenger in the evocation of the specific response 
of almost every type of differentiated cell by its 
appropriate extracellular messenger, which may be hormone, 
circulating metabolite, or neurotransmitter (79).
The discovery of cyclic adenosine monophosphate (cAMP) 
and the elucidation of its role as a second messenger in the 
action of peptide and amine hormones (80,82) coincided with 
the identification of Ca^+ as a coupling factor between 
excitation and response in excitable tissues (81). For a 
short period, it was thought there were two quite different 
models of cell activation: in excitable tissues Ca^+ coupled 
stimulus to response and in non-excitable tissues cAMP served 
this function. However, by the late 1960s it had become clear
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permission).
that a considerable overlap existed in the functions of these 
two intracellular messengers (79,83). It was also shown that 
adenyl cyclase and cAMP were abundant in neural tissues (83). 
As knowledge of the messenger roles of Ca^+ and cAMP has 
grown, it has become apparent that both act together in 
regulation of cell function.
For calcium mediated effects agonist/receptor binding 
causes both calcium release from an intracellular pool 
(plasma membrane and/or endoplasmic reticulum) and increased 
entry of extracellular calcium into the cell (51 ,55,82). This 
is followed by a sharp, but transient, rise in the [Ca^+ ]i 
then followed by a fall to near basal values. Then, despite 
the transient rise in [Ca^*]i, there is a sustained calcium 
influx and enhancement of cellular response (83). This 
augmented influx is nearly balanced by a high rate of calcium 
efflux, so that there is only a small rate of net 
accumulation of cellular calcium (83). The mitochondria serve 
as an intracellular "sink" for calcium and the non-ionic 
intramitrochondrial pool of calcium provides a means of 
stabilizing [Ca^+]i at any desirable level (65).
Small 'changes in [Ca^+]i cause dramatic changes in cell 
function. Cell activation could be described as a process of 
information flow from surface to interior (79). This process 
will be outlined as it applies to the vascular smooth muscle 
cell. Binding of the agonist to its specific membrane 
receptor represents the first step in the hormone mediated 
contractile process (Figure 4). Each pressor hormone has a 
specific type of receptor capable of initiating contraction 
(84). The activation signal generated by receptor occupancy
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is transmitted to a group of guanine nucleotide-binding 
proteins, the so-called G proteins which act as inter­
mediaries between the receptor and intracellular effector 
events. The signal initiated by hormone receptor binding is 
transmitted by G proteins to a group of membrane associated 
phospholipases (85). Hormone-activated phospholipase C acts 
on a particular inositol pool confined to the plasma membrane 
by hydrolysing inositol bisphosphate. This leads to the 
production of' the inositol trisphosphate (IP3 ) which enters 
the cytosol. At the time diacylglycerol is also prQduced but 
remains within the plane of the membrane (65).
It has been established that IP3 elicits the release of 
Ca^+ from the endoplasmic reticulum (65,84). The release of 
calcium ions from intracellular stores is the major cause of 
the cytosolic Ca^+ rise in response to stimulation. A minor 
component is said to be contributed by Ca^+ influx from the 
extracellular space and a metabolite of IP3 , IP4 is possibly 
a stimulator of this influx (84). A rise in the concentration 
of Ca^+ in the cell cytosol leads to an association of Ca^ + 
with receptor protein(s). The most ubiquitous and thoroughly 
studied of calcium receptor proteins is calmodulin (8 6 ). 
During cell activation [Ca^+]i rapidly rises from 0.1 i^M to 
1-4 ;uM, which is sufficient to shift calmodulin controlled 
response elements to a state of high activity (79). Another 
of these elements is the ATP driven Ca^+ pump in the plasma 
membrane (6 6). The mechanisms of [Ca^+]i normalization after 
the transient peak involve both Ca^+ efflux to the extra­
cellular space and re-uptake of Ca^+ by the endoplasmic 
reticulum (52,65).
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The second branch of vascular smooth muscle cell 
activation is dependent on protein kinase C. Activation of 
this enzyme by diacylglycerol causes vascular smooth muscle 
contraction that reaches a plateau after about 40 minutes. 
This contraction occurs without a [Ca^+ ]i peak and 
corresponds to the phase of latch-bridge formation, which is 
a state of contraction of the actomyosin complex that is 
long-lasting and consumes little energy (87). The molecular 
phenomena related to this contractile process are 
incompletely understood. Protein kinase C produces phos­
phorylation of several proteins, probably including acto­
myosin, myosin light-chain kinase, ionic channels and enzymes 
involved in the energy production and consumption. This phos­
phorylation results in structural modifications favouring the 
maintenance of prolonged contraction. The two pathways of 
vascular smooth muscle activation are not mutually 
independent and contraction observed in the presence of 
pressor hormones results from a combination of Ca^+-cal- 
modulin and protein kinase C-mediated mechanisms.
Section 3 - Methods of measurement of intracellular free 
calcium
1.3.1. Photoproteins (aequorin and obelin)
Aequorin is a 2000-dalton photoprotein from the marginal 
photocytes of the jellyfish, Aequorea forskalea (8 8 ). In the 
presence of calcium ions the protein emits photons and light 
which then can be detected by a suitable photomultiplier 
tube. The main advantage of aequorin as an indicator of
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ionized calcium are its sensitivity and lack of calcium- 
buffering. A major disadvantage is the difficulty of incor­
porating such a protein in the cell interior (89). In 1975 
Campbell and Dormer (90) succeeded in incorporating another 
photoprotein obelin into red blood cell ghosts using osmotic 
shock. Later Morgan and Morgan (91) used ethylene-glyco-bis 
(beta-aminoethylether) - N,N' - tetra-acetic acid (EGTA) to 
increase vascular smooth muscle cell membrane permeability to 
aequorin. Snowdowne and Borle (89) described the method of 
incorporating aequorin into the cells by-hyposmotic shock 
treatment. Later McNeil and Taylor (92) developed two methods 
for entrapping the photoprotein in cultured fibroblasts. In 
the first, single cells were individually micro-injected and 
ultrasensitive light detection was then employed to measure 
the resulting weak luminescence. In the second, aequorin was 
entrapped using "loading by scraping" technique in thousands 
or millions of cells to provide a larger total luminescent 
signal, and without the need for microinjection. The last 
method is probably particularly useful in mammalian cells 
grown in tissue culture (92).
1.3.2. Fluorescent probes
Quin-2 is one of a series of fluorescent calcium 
indicators described by Tsien (93) for measuring and 
manipulating cytosolic free calcium. As an indicator, Quin 2 
has advantages over previously available compounds and some 
drawbacks which are discussed later. Entry of indicators into 
intact cells is by permeation with subsequent hydrolysis of 
the tetra-acetoxymethyl esters (94,95,97). This advance 
allowed the first measurements of [Ca^+]i in a wide range of
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cells.
Quin 2, as shown in Figure 5, is a tetracarboxilie acid 
with 1 :1 stochiometry of calcium binding and a chelation claw 
resembling that of EGTA (94). Unlike EGTA, affinity for 
calcium is not significantly dependent on pH in the 
physiological range since the binding of calcium ions is not 
dependent on proton displacement,As a result, Quin 2 takes up 
and releases calcium more quickly than does EGTA and can 
follow increases in [Ca^+]i more rapidly than aequorin (99). 
Quin 2 fluorescence has an excitation peak near 340 nm and a 
measured emission peak near 490 nm (94,95). On binding one 
calcium ion, the fluorescence intensity of Quin 2 increases 
some 6.2 fold. Loading cells with Quin 2 is accomplished by 
incubation of the hydrophobic ester Quin 2/AM (Figure 5) with 
a suspension of cells and only some of the added Quin ends up 
inside the cells (between 15% and 30%). Because Quin 2 
fluorescence is rather weak, the optimum concentration of dye 
in cells is between 0.3 and 1 mM. This represents a com­
promise between concentrations of dye that cause least 
buffering of calcium and the requirement for an adequate 
signal (94/99).
Loading of Quin 2 into most mammalian cells is readily 
achieved and available evidence suggests that nearly all the 
trapped dye is in the cytoplasm (95,98). The incorporation of 
a calcium chelator can affect calcium handling. Effects of 
Quin 2 on cellular function may be caused by calcium 
buffering or by toxic effects of by-products of hydrolysis of 
Quin 2/AM. The most toxic is formaldehyde but most cells 
appear to cope with the low concentrations that are generated
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Figure 5
Structure of Ca2+ indicator Quin2 and its acetoxymethyl 
ester Quin2/AM.
(98). In many preparations loading of Quin 2 is reported not 
to affect indices of cell function. Examples of known adverse 
effects include: a lowering of ATP concentration, an increase 
in lactate production, and some degree of mitogenic 
stimulation in murine lymphocytes (98,99). Other effects 
noted have included activation of phosphorylase in hepato- 
cytes (1 0 0 ) and inhibition of glycolysis in human red cells 
with increased permeability to calcium (1 0 1).
It is possible to calculate the average resting [Ca^+]i, 
for a Quin 2-loaded cell suspension. The question is often 
raised as to whether the incorporation of a significant 
calcium buffering will alter the resting calcium level (99). 
Tsien et al (97,98) showed that in the presence of normal 
external calcium, the incorporation of extra buffering into 
the cytosol should not per se influence steady state calcium 
level since this is set by the permeability of the membrane 
and the'properties of the calcium pump. If cells are loaded 
in the absence of external calcium then the chelation of 
calcium by the incorporated Quin 2 does depress [Ca^+]i.
In many preparations, stimulus-evoked changes in [Ca^+]i 
can be easily measured and simple experimental manipulations 
have allowed investigation of the sources and nature of 
calcium influx (99). For example, it is assumed that a signal 
seen in the presence of very low external calcium results 
from the discharge of an internal pool. A signal seen in the 
presence of external calcium is assumed to result from com­
bined effects of discharge from an internal pool and influx 
across the plasma membrane. Influx can be inferred from the 
difference. The extra calcium buffering introduced by the
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Quin 2 inevitably alters the pattern of evoked changes in 
[Ca^+]i (94,98). The presence of Quin 2 probably has two 
effects on [Ca^+]i caused by short-lived increases in plasma 
membrane permeability: the rate of rise of [Ca^+]i is slowed , 
and the peak reached is reduced (96).
Although Quin 2 remains the most widely used fluorescent 
probe for clinical studies, a new generation of calcium 
indicators have been synthesised (102). The most commonly 
used of the new generation of fluorophores is Fura 2 which 
has a 30 fold brighter fluorescence than Quin 2, shows wave­
length shifts upon calcium binding and has a relatively low 
binding capacity for free calcium. Four significant 
advantages of Fura 2 over Quin 2 have been identified (103). 
Firstly, the Kd of Fura 2 enables intracellular Ca^ + concen­
trations to be determined at concentrations of fluorophore 
that have only half the buffering capacity of Quin 2. 
Secondly, the higher fluorescence intensity of Fura 2 means 
that at equal signal: autofluorescence ratios, Quin 2 has 60 
times more buffering capacity than Fura 2. A further advan­
tage of the lower intracellular Fura 2 concentrations is the 
reduced accumulation of formaldehyde, acetate and hydrogen 
ions in loaded cells. Lastly, the spectral shift on binding 
Ca^+ enables both the Ca^+-free and Ca^+-bound forms of the 
indicator to be monitored, thus providing a check that the 
fluorescent signals resulted from changes in Ca^+ binding and 
eliminating the possibility of artefactual changes in 
fluorescence.
Another, less widely used calcium-responsive fluorescent 
dye is Indo 1. Advantages include the 10-fold or greater
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difference in emission intensity at 400 nm between the 
chelated and the unbound species. The frequencies used for 
Indo 1 are further separated from cell autofluorescence 
signals than is the case for Fura 2. The dye undergoes a 
change in emission (instead of excitation) spectrum upon 
chelation (104).
The newer agents, Fura 2 and Indo 1 , may provide better 
information on intracellular calcium fluxes than Quin 2 and 
further developments can be expected in this area.
Section 4 - Cytosolic free calcium in hypertension
1.4.1. Platelets
Erne et al (105) was the first to report that the 
intracellular ionized calcium concentrations in platelets, 
measured with the fluorescent probe Quin 2, were higher in 
patients with essential hypertension than in normotensive 
subjects. They also reported very close correlations between 
cytosolic free calcium concentrations and blood pressure (r = 
0.883 for systolic and 0.931 for diastolic; p<0.001). 
Platelets are easily available in man and share many 
properties with vascular smooth muscle cells. Both cell types 
contain a calcium-dependent contractile system that couples 
hormone signals from various membrane receptors such as 
alpha-2-adrenoceptors or serotonergic receptors with contrac­
tile mechanisms (106). Activation in platelets causes shape 
change and aggregation (107). Platelets also show some 
alterations of calcium-dependent functions in essential 
hypertension. The examples include: increased aggregation due 
to adenosine diphosphate or adrenaline, enhanced shape change
after serotonin and increased secretion of beta-thrombo- 
globulin (108). In vascular smooth muscle cells from 
spontaneously hypertensive rats there is also enhanced 
calcium-influx-dependent vasoconstriction (41,51,62).
Erne et al (105) concluded that the observed relation­
ship between intracellular calcium concentration and blood 
pressure provided further evidence for the pathogenic role of 
intracellular free calcium in causing vasoconstriction in 
essential hypertension. Specifically, they suggested that 
defects in membrane permeability and/or alterations in ionic 
membrane pump mechanisms led to increased intracellular 
sodium and calcium concentrations. Further insights into 
possible causes of increased platelet free calcium in 
essential hypertension were obtained by Lindner et al (109). 
Incubation of platelets from normotensive subjects in plasma 
ultrafiltrate from patients with essential hypertension 
caused a marked increase in the cytosolic calcium con­
centration in these cells but no significant changes in 
cytosolic calcium were observed when normal platelets were 
incubated in plasma from normotensive subjects. High 
cytosolic calcium concentrations which occurred in cells from 
patients with essential hypertension were lowered into the 
normal range when platelets were incubated in plasma ultra­
filtrate from normotensive subjects. The findings supported 
the concept that a circulating factor (or factors) in hyper­
tension is responsible for the increased cytosolic calcium 
concentration in platelets.
In 1967 and on the basis of their classic parabiotic 
experiments, Dahl and colleagues (110) proposed that a
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humoral factor explained the rise in blood pressure in salt- 
sensitive hypertensive rats. Haddy and Overbeck (111) later 
suggested that a circulating sodium-potassium-pump inhibitor 
was involved in the pathogenesis of volume-expansion hyper­
tension. This substance, like ouabain, is a sodium-potassium 
ATPase inhibitor (112,113,126). Inhibition of active sodium 
transport then causes a rise in intracellular calcium, and 
the subsequent development of increased tone and raised blood 
pressure. Inhibition of the sodium pump may result in a 
small reduction in membrane potential and increased calcium 
influx through voltage dependent calcium channels (114). As 
an alternative, a rise in cell sodium could increase cell 
calcium by activation of the sodium/calcium exchanger in the 
plasma membrane (115). Thus, circulating humoral factors that 
primarily affect intracellular sodium content cause increases 
in cytosolic calcium concentration in platelets.
Although subsequent studies have tended to confirm the 
higher levels of intracellular calcium in platelets in 
essential hypertension (116-119), the differences in free 
calcium concentration observed in these studies have been 
smaller than reported by Erne et al (105). One possible 
weakness of the original study was the lack of adequate 
matching for age and body weight between hypertensive and 
control subjects. Severity of hypertension might also be 
relevant. The initial series (105) included a few hyper­
tensive emergencies; platelet turnover is increased in 
malignant hypertension and thrombocytopenia associated with 
microangiopathy then occurs quite frequently (1 2 0).
Lechi et al (119) measured platelet cytosolic calcium
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concentrations in response to various agonists. Adrenaline, 
noradrenaline and angiotensin II assayed over the concen­
tration range of 10“® to 10“  ^mol/1, had no effect on [Ca^+]i 
in either normal or hypertensive subjects. Stimulation with 
thrombin resulted in a concentration-dependent increase in 
[Ca^+]i which was due mainly to calcium influx from the 
extracellular space and to a lesser extent to calcium release 
from intracellular stores. Furthermore, the [Ca^+]i increase 
in the presence of 1 mmol / 1  external calcium was sig­
nificantly higher in the hypertensive patients than in the 
control subjects at all concentrations of thrombin tested. In 
the absence of extracellular calcium, release from intra­
cellular stores induced by thrombin was similar in hyper­
tensive and normotensive subjects. The difference between the 
two groups appeared to be in calcium influx from the extra­
cellular space. Thus, the increased response of platelets to 
thrombin in hypertensive subjects could involve a receptor- 
operated mechanism linked to increased transport of calcium 
across the cell membrane. This interpretation is in line with 
cell membrane abnormalities present in arterial hypertension 
and expressed as impaired homeostasis of intracellular 
calcium (62,76).
There is experimental evidence that membrane cholesterol 
and its oxidised derivatives are critical determinants of 
calcium fluxes through biomembranes. In human erythrocytes, 
it has been shown that transmembranous calcium influx through 
the calcium channel correlates with the proportion of 
cholesterol in the membrane (121). Locher et al (122) has 
measured effects of cholesterol on intracellular free calcium
48
concentration in human platelets. An increasing proportion of 
cholesterol incorporated into platelet membrane caused a 
significant rise in intracellular calcium which led to the 
hypothesis that membrane cholesterol contributed to the 
regulation of cellular calcium metabolism.
In the spontaneously hypertensive rat, studies on free 
calcium levels in platelets have given contradictory results. 
Bruschi et al (123) reported significantly elevated [Ca^+]i 
in platelets of 8- and 20-week old SHR in comparison with WKY 
but no difference in [Ca^]+ at 4 weeks. On average, the 
difference in levels between SHR and WKY showed a tendency to 
increase with age and reflected the divergence of arterial 
pressure. In contrast Zimlichman et al (124) could find no 
differences in baseline levels of cytosolic calcium or in the 
kinetics of changes in [Ca^+]i between the SHR and WKY rats 
studied at a time when highly significant differences in 
average blood pressure were obtained between the groups. They 
concluded that the results were inconsistent with the hypo­
thesis that intracellular calcium in platelets at rest or in 
response to agonists could be determined by the same factors 
that cause high blood pressure in SHR. They hypothesised 
further that increased platelet aggregability described in 
SHR was related to the abnormalities in intracellular 
mechanism triggered by intracellular calcium rather than 
responsiveness of cytosolic calcium per se.
1.4.2. White blood cells
Several studies have examined intracellular calcium 
concentrations in white blood cells in human and experimental
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hypertension with conflicting results. Shore et al (125) 
measured free calcium in mononuclear leucocytes of normo­
tensive and hypertensive subjects but could find no sig­
nificant difference between leucocyte [Ca^+ ]i in the two 
groups.
Bing et al (127) studied the relationship between intra­
cellular concentrations of calcium and sodium in white blood 
cells and blood pressure in patients with essential hyper­
tension, normal controls and subjects with contrasting family 
histories of hypertension. They failed to show elevation of 
[Ca^+]i in leucocytes of untreated essential hypertensive 
patients compared with those of normotensive subjects with or 
without a family history of high blood pressure. In con­
trast, there was a significant positive correlation between 
[Ca^+]i and blood pressure in subjects with normal pressures 
and negative family histories, but the relationship was lost 
if subjects with a positive family history or hypertensive 
patients were included. Again there did not seem to be any 
relationship between [Na+]i and [Ca^+]i in leucocytes.
Oshima et al (128) studied intracellular calcium, sodium 
and potassium in the lymphocytes in essential hypertension. 
Intracellular calcium and sodium were significantly increased 
in lymphocytes of hypertensive patients, [Na+]i and [Ca^+]i 
were correlated in both groups. [Ca+]i and [Na+ ]i were both 
inversely related to plasma renin activity in the hyper­
tensive group, but not related to blood pressure. These 
findings, discrepant with other findings in white blood cells 
in essential hypertension, may be accounted for by 
characteristics of the hypertensive group such as ethnic
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origin or renin profile. Differences in dietary sodium intake 
could be relevant. Changes in salt intake alter [Ca^+]i in 
lymphocytes (129): if salt intake was higher in one of the 
groups, the difference in [Ca^+]i could be diminished. A 
close positive correlation observed between [Na+ ]i and 
[Ca^+]i in the study by Oshima et al (128) indicates a link 
between calcium handling and sodium transport across the cell 
membrane in patients with essential hypertension and normo­
tensive subjects. The definition of the cell type as lympho­
cytes was different from the earlier studies.
There is more agreement on calcium levels in white blood 
cells of genetically hypertensive rats. Bruschi et al (130) 
were first to report that cytosolic free Ca^+ in lymphocytes 
of spontaneously hypertensive rats was increased as compared 
to WKY control rats. Increasing the extracellular Ca^+ con­
centration 1 0-fold to 1 0 mM induced only a modest rise of 
intracellular free Ca^+ concentration. The extent of this 
rise was comparable in cells from SHR and WKY. Decreasing 
extracellular Ca^+ to about 100 nM by the addition of EGTA 
caused a 2 0% fall of cytoplasmic calcium and this reduction 
was similar in hypertensive and normotensive rats. Homeo­
stasis of intracellular calcium was maintained despite 
extreme variations of external calcium. This could reflect 
low membrane permeability to calcium ions or effective com­
pensatory mechanisms such as activation of membrane Ca^+- 
ATPase or uptake into intracellular stores. The important 
point is that the SHR-WKY difference was maintained at any 
given concentration of extracellular calcium. Furspan and 
Bohr (73) measured free intracellular calcium concentration
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in lymphocytes from stroke prone spontaneously hypertensive 
rats (SHRSP) and Wistar-Kyoto control rats (WKY) using Quin 
2. Like Bruschi et al they found higher concentrations of 
intracellular free calcium in lymphocytes from the SHRSP than 
in those from the WKY. The same laboratory has presented 
evidence for increased membrane permeability to sodium and 
potassium in genetic hypertension (131). Net passive influx 
of sodium and efflux of potassium were higher in lymphocytes 
from SHRSP than in lymphocytes from WKY.
A subsequent study by Furspan and colleagues revealed a 
genetic association between net potassium efflux of lympho­
cytes and blood pressure when these traits were followed in 
the progenies (F2 and backcross) of WKY and SHRSP matings 
(132). They postulated that the change in potassium 
permeability is secondary to a primary genetic defect of 
altered calcium handling by the lymphocyte membrane, which 
results in an elevated intracellular free calcium concen­
tration. This elevation in turn activates the calcium- 
sensitive potassium efflux channels. Further evidence of a 
membrane abnormality in lymphocytes was found in the 
observation'that in these cells from WKY, SHR and SHRSP, the 
net sodium influx varied inversely with the external calcium 
concentration. At all concentrations of calcium tested, the 
net sodium and potassium fluxes were higher in the lympho­
cytes from the SHR and SHRSP than in those from WKY (73). The 
greater fluxes were interpreted as consistent with a reduced 
calcium-binding capacity of the plasma membranes of lympho­
cytes from SHR and SHRSP. This hypothesis has been discussed 
in detail in section 2 (1.2.3).
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1.4.3. Vascular smooth muscle cells
For the study of intracellular calcium in man platelets 
or leucocytes have the advantage of convenience, but the 
disadvantage that levels in these blood cells may not reflect 
levels in vascular myocytes. Changes in electrical activity 
of the cell membrane or interaction of pharmacological agents 
with membrane receptors cause either a decrease or increase 
in cytosolic calcium concentration and thereby alter the 
contractile state of the myocyte (3,51,52,55,59).
A key issue in the study of genetic hypertension is the 
putative role of alterations in cellular Ca^+ metabolism in 
the maintenance of an increase in basal vascular tone or 
reactivity (5h,52,62,1 33,1 34). Several lines of evidence 
support this contention. Cauvin et al (55,135) measured 
^Ca^+ influx in vascular smooth muscle from the resistance 
vessels of SHR and WKY (Figure 6). The influx was greater 
through the "leak channel", the receptor operated channel and 
the potential sensitive channel in the smooth muscle from the 
SHR than it was in that from the WKY. In the SHR, Mulvany et 
al found that mesenteric resistance vessels showed 
exaggerated contractile responses to noradrenaline compared 
with the normotensive WKY rats (136). This increased con­
tractility seemed to result from the increase in .both Ca^+ 
leak and activity of excitable Ca^+ channels as indicated in 
Figure 6. Bukoski et al (137) demonstrated a similar enhanced 
influx of radiolabelled Ca^+ into cultured vascular smooth 
muscle cells from SHR. .
Other evidence comes from observations of a decreased 
capacity of subcellular membrane fractions of aortic (138)
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Figure 6 ^ C a 2+ influx in the resistance vessels
9+Cdr influx was measured over a 90-sec. period in vessels
exposed to Ca2+ - labelled physiologic salt solution: (PSS)
(rest) or Ca2+-PSS +10'^M noradrenaline (NE) or 80mM K+ -PSS,
and then washed for 20 min. in ice-cold Ca2 + -PSS containing
2mM EGTA. Resting Ca2+ influx and Ca2+ influx in the presence
of NE or 80mM K+ were significantly elevated in the SHR vessels
as compared to those of the WKY rat (P<0.05) when expressed as 
9+Ca^ flux per unit vessel weight. (From reference 55 with 
permission.)
and mesenteric arteries (139) to bind Ca^+ in the presence of 
ATP which may result in impairment of control of high intra­
cellular calcium concentrations in smooth muscle from the 
hypertensive rat.
However, direct studies of resting, unstimulated free 
cytosolic calcium in vascular smooth muscle cells have given 
contradictory results. Compared with control animals, it has 
been variously reported that intracellular Ca^+ of the SHR is 
elevated (140), depressed (141), or unchanged (142,143). 
Nabika et al (142.) measured cytosolic free calcium con­
centrations in cultured aortic smooth muscle cells obtained 
from 5 week old (prehypertensive) SHR and WKY rats. Cell 
suspensions were prepared and loaded with Quin 2/AM. The mean 
resting values of [Ca^+]i were almost identical in WKY and 
SHR (114 ± 6 nM [SEM] and 116 ± 5 nM, respectively). The same 
study analysed intracellular Ca^+ responses to two potent 
va socons.tr ictor substances: angiotensin II and arginine-
vasopressin (AVP). These peptides bind to specific receptors 
on vascular smooth muscle cells and cause Ca^+ entry or Ca^+ 
mobilization from intracellular stores. Angiotensin II caused 
concentration-dependent [Ca^+]i increases but there were no 
significant differences between the responses of smooth 
muscle cells from WKY and SHR. AVP caused smaller [Ca^+ ]i 
increases than angiotensin but vascular smooth muscle cells 
from SHR showed greater responses than controls. The cells 
used in the experiments described were obtained from pre­
hypertensive rats: the possibility that high [Ca^+]i is a
consequence of high blood pressure is not excluded. Humoral 
or neuronal factors not present in tissue culture may be
necessary to maintain high [Ca^+ ]i in SHR cells. The 
physiological significance of enhanced responsiveness to AVP 
is doubtful because the concentration of AVP was much higher 
than circulates in plasma (144). However, Hamley et al (145) 
found an immunoreactive vasopressin-like peptide in the 
vessel wall and suggested that AVP might control vascular 
tone as a neurotransmitter. They proposed that AVP may be 
present in peripheral nerve endings of vascular wall at 
concentrations higher than those found in plasma and that 
enhanced responsiveness to AVP could contribute to the 
pathogenesis of hypertension.
Bukoski et al (143) measured basal and agonist- 
stimulated concentrations of intracellular Ca^+ in resistance 
vessels of 1 2 week old hypertensive and normotensive rats. 
The measurements were done in isolated vessel segments using 
Fura 2/AM and a fluorescence microscope interfaced with a 
dual excitation wavelength fluorometer. They found no 
difference in resting concentrations of intracellular calcium 
in isolated arterioles of the SHR as compared to those of the 
WKY. When the vessels were stimulated by noradrenaline, there 
was a difference in the transient increase in Ca^+ concen­
tration with arterioles of SHR exhibiting significantly lower 
response to 1 and 1 0 jiM norepinephrine. The results did not 
support the hypothesis that increased sensitivity of vascular 
smooth muscle of the SHR to catecholamines or an increase in 
resting tone of resistance vessels is the result of an 
inherently greater level of intracellular Ca^+ (143).
Sugiyama et al (140) measured the absolute values of 
[Ca^+]i in single vascular smooth muscle cells using the UV-
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laser and Ca^+-sensitive probe Indo-1. This system has 
several advantages: 1) [Ca^+]i is calculated not from the
fluorescence intensity but from the fluorescence ratio; the 
photobleaching of Indo-1 and intracellular Indo-1 con­
centration have no effect on the calculation of [Ca^+]i. 2) 
Use of a laser to excite the dye allows the low energy 
excitation to produce a high intensity of fluorescence from 
low concentrations of intracellular Indo-1. Using this method 
the mean [Ca^+]i in 8 and 12 week old SHR were significantly 
higher than those in 8 and 12 week old WKY, but intracellular 
calcium concentrations were not higher in four week old 
(prehypertensive) SHR. They also studied intracellular free 
calcium in vascular smooth muscle cells from WKY and SHR in 
primary culture, and in the 6th passage. In the 6th passage 
cultured vascular smooth muscle cells, the haemodynamic 
effects of the high blood pressure in SHR on [Ca^+]i in. vivo 
should have disappeared. However, intracellular calcium con­
centrations were the same in primary culture as in passaged 
cells and the increase in [Ca^+]i in SHR was maintained. 
These results are consistent with the idea that maintenance 
of [Ca^+]i levels of vascular smooth muscle cells in SHR is 
genetically regulated and that high levels are not a con­
sequence of high blood pressure.
The results of measurements of [Ca^+]i, in platelets, 
white blood cells and vascular smooth muscle cells in hyper­
tensive man and in spontaneously hypertensive rat are 
summarised in Table 1. .
Developments in methods of measuring cytosolic free 
calcium should allow more precise estimations of resting and
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TABLE 1
Resting free cytosolic calcium [Ca^+]i in platelets, white 
blood cells and vascular smooth muscle cells in hypertensive 
man and in the spontaneously hypertensive rat
Cell type Source of 
tissue
Method Result Ref
Platelets Man Quin 2 ? 1 05
Platelets Man Quin 2 t 109
Platelets Man Quin 2 r 116
Platelets Man Quin 2 r 117
Platelets Man Quin 2 - 118
Platelets Man Quin 2 t 119
Platelets SHR/WKY - Quin 2 r 1 23
Mononuclear
leucocytes
Man Quin 2 - 125
Leucocytes Man Quin 2 - 1 27
Lymphocytes Man Quin 2 r 128
Lymphocytes SHR/WKY Quin 2 t - 1 30
Lymphocytes SHR/WKY Quin 2 r 73
VSMC SHR/WKY ^Ca^ + inf lux t 1 35
VSMC SHR/WKY ^Ca^ + inf lux r 137
VSMC SHR/WKY Quin 2 - 1 42
VSMC SHR/WKY Fura 2 - 1 43
VSMC SHR/WKY Indo 1 t 1 40
Arrows indicate direction of difference from normotensive 
controls: (-) indicates that there were no differences
between hypertensive and normotensive subjects or SHR and 
WKY. Vascular smooth muscle cells - VSMC
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stimulated intracellular calcium in intact living cells under 
physiological conditions, and may eventually allow 
simultaneous measurements of [Ca^+ ]i and contractile 
activity.
1.4.4. Effects of blood pressure lowering treatment
Effects of antihypertensive therapy on free cytosolic 
calcium concentration in human platelets have been described 
(1 05,1 09,1 1 8,1 46). Erne et al (105) initially reported that 
antihypertensive treatment with calcium-channel blockers, 
beta-adrenoceptor blockers and thiazide diuretics all 
resulted in a fall in levels of cytosolic calcium. When all 
treated patients (n=33) were analysed, the treatment-induced 
changes in platelet calcium levels correlated with the 
changes in systolic and diastolic pressures. Lindner et al 
(109) also observed that the intracellular free calcium con­
centration in platelets decreased into the normal range 
during successful treatment of hypertension with either a 
calcium-channel blocker (nicardipine) or an angiotensin- 
converting enzyme inhibitor (lisinopril). In addition, when 
platelet calcium was measured repeatedly over a range of 
blood pressures in the same patients, these values were 
directly correlated in each treatment group. Lenz et al (118) 
examined the acute effects of nifedipine and captopril on 
free intracellular platelet calcium in patients with 
essential hypertension. Both drugs lowered blood pressure 
within 60 minutes but platelet calcium was only lowered by 
nifedipine and not by captopril. There was no correlation 
between blood pressure reductions and falls in platelet 
calcium. The authors speculated that calcium changes observed
during chronic antihypertensive therapy (105,109) might be a 
consequence rather than a cause of the blood pressure 
reduction. McVeigh et al (146) studied platelet free intra­
cellular calcium levels during a placebo-controlled study of 
the effects of increasing doses of thiazide diuretic in mild 
essential hypertension. After 8 weeks' therapy 125 and 150 jig 
of cyclopenthiazide produced significant decrements of blood 
pressure compared with placebo but 50 jig had no effect. 
Platelet [Ca^+]i levels decreased to similar extent in each 
of the three treatment groups, as well as in the placebo 
group. No correlation between decrease in blood pressure and 
cytosolic calcium was evident. These findings were incon­
sistent with the hypothesis that changes in platelet [Ca^+]i 
could be determined by the same factors that control blood 
pressure.
Various classes of blood pressure-lowering drugs have 
been shown to lower free cytosolic calcium concentration in 
platelets. The data available are not consistent about the 
relationship between changes in intracellular calcium and 
blood pressure. It is too early to say if changes in intra­
cellular calcium are a cause or a consequence of changes in 
blood pressure.
1.4.5. Effects of dietary calcium supplementation
Epidemiological studies, summarised in Section 1 , have 
led to the hypothesis that dietary deficiency of calcium has 
a role in the pathogenesis of essential hypertension. Some 
intervention studies have found that an increased dietary 
intake of calcium has a blood pressure-lowering effect in
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essential (27) and experimental hypertension (14). It remains 
uncertain whether normalization of extracellular ionized 
calcium is a necessary part of this effect. In contrast to 
extracellular ionized calcium, intracellular free calcium, 
which tends to be elevated before treatment, decreases as 
blood pressure is lowered by several drugs (105). McCarron et 
al (147) has proposed that dietary calcium supplementation 
acts by correcting an imbalance between extracellular and 
intracellular free calcium concentrations thereby causing 
vascular smooth muscle to become more efficient or.effective 
in handling intracellular free calcium.
Furspan et al (31) made comparisons of the effects of 
feeding normal (1%) or high (2.5%) calcium diets to SHRSP for 
nine weeks. Initial values for sodium and potassium fluxes, 
intracellular ionized calcium and blood pressure were 
elevated in the SHRSP compared to the WKY. The high calcium 
diet caused a significant increase of extracellular ionized 
calcium accompanied by a normalization of sodium and 
potassium fluxes, [Ca^+ ]i and blood pressure. Felodipine 
treatment had the same effect (148).
The mechanisms linking dietary calcium manipulations 
with blood pressure are not well defined and further studies 
are needed to examine whether dietary supplements of calcium 
normalize intracellular free calcium. The paradox that blood 
pressure is lowered both by increased calcium intake and 
calcium channel blockers may then be resolved.
Section 5 - Parathyroid hormone and blood pressure regulation
1.5.1. Parathyroid hormone; structure and biological
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actions
Parathyroid hormone is an 84 amino-acid single chain 
polypeptide. The amino-acid sequences of bovine, porcine and 
human parathyroid hormone (PTH) are defined (149). The N- 
terminal 27 amino-acids seem to be essential for biological 
activity but full activity requires the segment 1 to 3.4. The 
determinant of secretion of parathyroid hormone is the plasma 
concentration of calcium ions. A physiological increase in 
PTH secretion appears to depend _in the short-term on release 
of stored peptide. There is little evidence that PTH 
secretion is controlled at transcriptional or translational 
levels. Short-term changes in secretion involve calcium 
effects on degradation of PTH in parathyroid cells and long­
term changes are mediated by hyperplasia or atrophy of the 
glandular tissue (150). Parathyroid hormone in plasma 
measured by radioimmunoassay is heterogenous. The main frag­
ment of the hormone has a molecular weight near 6000 and 
corresponds to the C-terminal portion of the molecule; there 
are also amino-terminal fragments which may have biological 
activity, as well as small amounts of the complete 84 amino- 
acid mature hormone. Most assays measure the dominant C- 
terminal fragment and therefore reflect long-term changes in 
hormone secretion or removal rather than rapid physiological 
or pathological variations (22,151). Novel assays based on 
monoclonal antibodies which measure intact 1 -84 parathyroid 
hormone are under development (21,152).
Parathyroid hormone acts on kidney, bone and intestinal 
tract. In the kidney the hormone has three separate effects; 
enhancement of phosphate excretion, increased reabsorption of
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calcium and promotion of conversion of 25-hydroxycholecal- 
ciferol to the highly active 1 ,25-dihydroxycholecalciferol. 
These combine to cause an increase in the plasma con­
centration of calcium ions. The second messengers are cAMP 
and intracellular calcium (153,154). Parathyroid hormone 
causes not only an increase in intracellular cAMP, but also 
spillover of cAMP into the urine (155). Evidence that an 
increase in intracellular calcium is involved is less clear. 
In bone, PTH enhances osteoclastic activity (150). In 
addition to this action which produces bone destruction, 
there is some evidence that PTH can have an anabolic effect 
on bone so that net bone mass is increased. The cellular 
mechanisms involved in the action of the parathyroid hormone 
on bone presumably resemble those in the kidney: increase in 
cAMP, perhaps associated with an increase in intracellular 
calcium. The action of parathyroid hormone in the intestinal 
tract is an indirect one, exerted via the increased renal 
production of calcitriol. The net effect is to enhance 
absorption of calcium and phosphorus (153).
1.5.2. Actions of parathyroid hormone in the cardio­
vascular system 
Studies from several centres have suggested that the 
cardiovascular system is another target for parathyroid 
hormone action (1 56-1 59). Charbon (156) and later Pang et al 
(160) have shown that injections of parathyroid extract or 
synthetic bovine PTH (1-34) cause a rapid reduction in 
systemic blood pressure in dogs. This hypotensive effect is 
reproducible, dose dependent (161) and caused by systemic
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vasodilation. Both purified bovine PTH (1-84) and its syn­
thetic amino-terminal fragment (1-34) PTH increase coronary, 
renal, hepatic, gastric and pancreatic blood flow in the dog 
(162,163). Bolus injection or short-term infusion of para­
thyroid extract, (1-84) PTH and (1-34) PTH (1 60,1 64) decrease 
blood pressure in a variety of normotensive anaesthetised 
vertebrates. Studies in spontaneously hypertensive rats, in 
the two-kidney one-clip model of hypertension and in deoxy­
corticosterone and salt hypertension in rats showed that 
acute administration of (1-84) and (1-34) PTH reduces blood 
pressure (1 65, 1 66). The vasodilatory action has been 
demonstrated in the perfused rat hindlimb and isolated rabbit 
aorta preparation and it is not blocked by propranolol, 
phentolamine, atropine or promethazine (163). Indomethacin, a 
cycloxygenase inhibitor, seems to reduce the hypotensive 
action of PTH (159), which implicates vasodilatory prosta­
glandins. The only specific agents which inhibit these vaso­
dilator effects are synthetic analogues of PTH which act as 
competitive antagonists, at least in the kidney (158).
PTH interacts with the smooth muscle cells of vascular 
tissue via stimulation of specific membrane receptors. 
Nickols (167) showed that PTH relaxed precontracted aortic 
strips, increased cAMP in cultured vascular smooth muscle 
cells and stimulated adenylate cyclase in membrane 
preparations in a dose-dependent manner.
Besides vasodilation, PTH administration causes an 
increase of heart rate -in anaesthetised dogs which is not a 
result of baroreceptor activation (158). Crass et al (168) 
have described concentration-dependent vasodilation of the
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coronary artery. At higher doses, there is stimulation of 
left ventricular isometric contractile force and an increase 
in spontaneous heart rate. PTH also increases the frequency 
at which rat heart cells beat in culture and stimulates 
cAMP production (157).
1.5.3. Cyclic AMP and intracellular calcium - synarchic 
second messengers for the parathyroid hormone
Increased entry of calcium into vascular smooth muscle 
normally causes vasoconstriction (2,3,41,51-55,57-59), but 
PTH probably does not enhance entry of calcium into smooth 
muscle cells (159). Data from Pang et al (163,171) suggest 
that the hormone blocks entry of calcium. (1-34) PTH appeared 
to reduce the low-affinity lanthanum-resistant pool of 
calcium in the tail artery of the rat and in mesenteric 
artery of the chicken.
In more recent studies, Pang et al (personal com­
munication) examined the effect of the bovine PTH fragment 
(1-34) on the L voltage-dependent calcium channel currents of 
the rat tail artery smooth muscle cells, using the patch 
clamp technique. In the majority of cells studied, the L 
channel currents were inhibited by PTH and this inhibition 
could be reversed by calcium channel agonist BAY-K 8644. The 
authors interpreted these data as suggesting that the 
mechanism of vasodilation produced by PTH may be mediated by 
the inhibition of L voltage-dependent calcium channels in 
vascular smooth muscle.
Rasmussen (154) has proposed that PTH acts through two 
second messenger systems, namely cAMP and intracellular free
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calcium. This dichotomy underlies the conflicting findings 
and conclusions concerning the cellular responses to the 
hormone. In smooth muscle the acute actions of PTH are 
primarily mediated by cAMP, which acts in two ways: firstly,
it stimulates phosphorylation of myosin light chain kinase 
(169) and secondly, it lowers intracellular ionized calcium 
concentrations (170,171). Both processes promote muscle 
relaxation.
Part of the effect of PTH on the renal proximal tubule 
is also mediated through cAMP, and in this regard both PTH 
and cAMP inhibit the Na+/H+ exchanger at the apical portion 
of this segment of the nephron (172). These observations 
raise an intriguing possibility concerning the role of PTH in 
salt-sensitive essential hypertension. Elevated serum con­
centrations of this hormone may serve to counteract the 
vasoconstriction associated with increased activity of the 
Na+/H+ exchanger in renal proximal tubules of salt sensitive 
individuals. Resnick et al (18) showed that patients with 
lower serum ionized calcium are primarily low-renin hyper­
tensives. It is of interest that black and older patients 
with essential hypertension, who compromise a major portion 
of this group, manifest high levels of serum PTH (1 73,1 74). 
Moreover, a higher salt intake is associated with an increase 
in serum PTH concentrations in hypertensive blacks (175). 
Aviv (176) has hypothesised that PTH elevation in salt sen­
sitive essential hypertension is a compensatory process, 
attenuating both the hyperactive Na + /H+ antiport in the 
proximal tubule and the increased peripheral vascular 
resistance. Hypertension, observed in primary and secondary
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hyperparathyroidism, may not be directly related to elevated 
PTH levels but to other primary metabolic abnormalities.
1.5.4. Primary hyperparathyroidism
Primary hyperparathyroidism is due to oversecretion of 
parathyroid hormone. The pathogenesis is not understood. Most 
patients have overactivity of a single gland which contains 
an adenoma. It has been suggested that adenoma may be a 
consequence of parathyroid hyperplasia because the con­
stituent cells are polyclonal (177). This question has been 
re-examined by Arnold et al (178), , who came to the 
alternative view that adenomas are often, if not always 
composed of a clone of cells. Firstly, they found evidence 
that the parathyroid hormone gene had undergone a clonal 
rearrangement; secondly, clonality was inferred from the 
evaluation of X chromosomes in parathyroid adenomas obtained 
from women. A clonal abnormality implies that the underlying 
disturbance in DNA structure. originated in one cell as a 
result of a somatic mutation (179).
In contrast to sporadic adenomas, hereditary distur­
bances or germ-line mutations that cause primary hyperpara­
thyroidism are almost always associated with generalised 
hyperplasia of the parathyroids. Familial hypocalciuric 
(benign) hypercalcaemia is such a condition possibly due to 
impaired feedback of calcium on secretion of the parathyroid 
hormone. Heterozygotes with a single abnormal gene have life­
long hypercalcaemia and normal or slightly hyperplastic para­
thyroid glands; homozygotes have life-threatening hyper­
calcaemia and severe parathyroid hyperplasia which are both 
evident at birth (180). In type I familial multiple endocrine
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neoplasia, parathyroid hyperplasia is associated with benign 
pituitary tumours and benign or malignant isl/.-it-cell tumours 
of the pancreas. The mutant gene has been localised to a 
region on chromosome 11 (181). In type II familial multiple 
endocrine neoplasia, parathyroid hyperplasia is associated 
with phaeochromocytoma and with benign or malignant pro­
liferation of calcitonin-containing cells of the thyroid 
gland. The mutant gene has been mapped to a region near the 
centromere of chromosome 10 (182).
The clonality of parathyroid adenomas has important 
clinical implications. It provides a basis for the hypothesis 
that the pathogenesis of adenoma is fundamentally different 
from that of hyperplasia. A diagnosis of adenoma usually 
implies that family screening is not necessary, that subtotal 
parathyroidectomy with its increased risk of permanent hypo­
parathyroidism need not be performed, and that the risk of 
postoperative recurrent hyperparathyroidism is low (179). The 
concept that adenoma results from somatic gene mutation is 
supported by the suggestion that parathyroid adenoma may be 
induced by irradiation (183).
In 1934, and only ten years after the first operation
for removal of parathyroid tumour, Albright et al (184) 
defined the condition in a paper entitled "Hyperpara­
thyroidism -.a common and polymorphic condition as 
illustrated by seventeen proved cases in one clinic". There 
has been increasing awareness that primary hyperpara­
thyroidism is not rare and often occurs as a relatively mild
condition lacking the florid renal and skeletal
manifestations found in the original cases. The introduction
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of multiple channel autoanalysers into clinical practice has 
greatly increased the apparent incidence of the disorder 
(45,185-188). Current estimates of the prevalence of primary 
hyperparathyroidism in hospital populations are 1 00-200 per
100.000 (185,186). A report from Sweden (189) found that the 
figure in adult workers was as high as. 520 per 1 00,000. In 
Rochester, Minnesota,’ the addition of calcium to the 12 unit 
serum biochemistry profile increased the number of known 
cases of primary hyperparathyroidism four-fold (45). The same 
study gave an age-adjusted rate of 27.7 per 1 00,000 with an 
annual incidence of 188 per 100,000 in women over 60. By 
extrapolating, it was argued that there might be 35,000 to
86.00 0 new cases of primary hyperparathyroidism per year in 
the United States. Mundy et al (190) reported similar 
findings from an urban community survey in England. The 
annual incidence in Birmingham was calculated at 25 cases per 
100,000; and this figure if true for England as a whole, gave 
an annual incidence of 10,000.
Primary hyperparathyroidism is a disease of protean 
manifestations (191). In its mildest form there are no 
symptoms or signs, and the diagnosis is only suspected after 
routine determinations of serum calcium. Symptomatic disease 
develops insidiously over a period of years. Renal colic is 
the most common symptom occurring in 25-35 per cent of cases, 
with nephrocalcinosis occurring less often. Stones are 
usually composed of calcium oxalate and less commonly of 
calcium phosphate. In a few patients the condition progresses 
rapidly, with marked hypercalcaemia, debility, bone pain and 
sometimes pathological fractures. Bone disease in hyperpara­
thyroidism is now quite rare but may present with bone pain, 
pathological fractures, bone cysts, or localised swellings of 
bone described as "epulis" of the jaw or "brown tumours" of 
bone, which comprise accumulated osteoclasts, osteoblasts and 
fibrous tissue (192). Peptic ulcer and chronic pancreatitis 
occur with increased frequency. Hyperparathyroidism as a 
component of the multiple endocrine neoplasia type I (MEN I) 
syndrome may be associated with the Zollinger-Ellison syn­
drome (193). Neurological abnormalities in hyperpara­
thyroidism include emotional lability, slow mentation, poor 
memory, depression and neuromuscular abnormalities. Some 
signs and symptoms in hyperparathyroidism may be secondary to 
hypercalcaemia per se. Polyuria, polydipsia and constipation 
are common. Other less frequent abnormalities include "band 
keratopathy", pruritus, subconjunctival deposits of calcium, 
and ectopic calcification of lungs, kidneys, arteries and 
skin (184,191). An association between primary hyperpara­
thyroidism and high blood pressure has been suggested by 
several studies (43-45,194,195) and will be discussed in 
detail in chapter 1 .5.4.
Radiographic evidence of hyperparathyroidism includes 
subperiosteal resorption (best recognised in the phalanges 
and distal portions of the clavicles), generalised osteopenia 
or osteoporosis, demineralisation ("salt and pepper pattern" 
of the skull), bone cysts or brown tumours (192). Hypercal­
caemia accompanied by hypophosphataemia is the typical 
feature of primary hyperparathyroidism. The increased calcium 
concentration in serum reflects the action of parathyroid 
hormone on the kidney and the skeleton and stimulation of
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1 ,25(OH)2 vitamin production resulting in increased
calcium absorption from the gut. About half of all patients 
with hypercalcaemia detected in the hospital clinics have 
primary hyperparathyroidism, and hypercalcaemia detected in 
surveys of healthy populations is caused by primary hyper­
parathyroidism in most instances (186). PTH causes hypophos- 
phataemia by increasing renal clearance of phosphate, once 
used as a diagnostic test. Laboratory methods that now con­
tribute to the diagnosis include radioimmunoassay of PTH, 
urinary clearance of cAMP, and determination of vitamin D 
metabolites in plasma. Concentrations of PTH in plasma are 
elevated in hyperparathyroidism and low or undetectable in 
other forms of hypercalcaemia. Some aspects of cAMP as a 
second messenger for parathyroid hormone have been discussed 
in the previous chapter. Renal tubular cells.express specific 
membrane receptors for PTH and the increase in intracellular 
cAMP in response to PTH is reflected in the appearance of 
this nucleotide in the urine (155).
Surgical correction of primary hyperparathyroidism 
results in correction of hypercalcaemia in most cases. There 
are several methods of localising abnormal parathyroid tissue 
before surgery. Computerised axial tomography, ultrasono­
graphy or radiothallium scanning are said to have 60-90% 
success rates in previously unoperated cases (196,197). 
Angiography and selective venous catheterisation should be 
reserved for instances of recurrence or persistence of hyper­
parathyroidism after initial neck exploration (198). Purnell 
et al (199) identified four groups of patients with primary 
hyperparathyroidism, based on large clinical experience at
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the Mayo Clinic. The first category comprised patients with 
severe hypercalcaemia and bone or renal disease. Surgical 
removal of abnormal parathyroid tissue is clearly indicated 
in this group and an accomplished parathyroid surgeon can 
achieve this in 90 per cent of patients not previously 
operated on. In the second category are patients who have had 
unsuccessful surgical treatment or recurrence of hyperpara­
thyroidism after a successful operation. In this group the 
problem is to locate the abnormal parathyroid tissue, pre­
ferably before surgery. The third and largest category in­
cludes patien_ts with so called "asymptomatic" or "bio­
chemical" disease, with mild hypercalcaemia (serum calcium 
less than 2.75 mmol/1), high PTH concentrations, no 
radiological evidence of bone disease, normal renal function 
and without urinary tract stones. The best treatment for 
these patients is not decided (199,200). The fourth category 
includes patients who are unfit for surgery or in whom 
surgery has repeatedly failed and who are candidates for 
medical treatment.
The preferred surgical approach is to search one side of 
the' neck first. If an adenoma and a normal gland on that side 
are proved by biopsy (frozen sections), the adenoma is 
removed and the wound closed. If a lesion is not found then 
the procedure is repeated on the other side until all four 
glands are identified (191). If several glands are hyper­
plastic then all parathyroid tissue should be removed apart 
from about 50 mg of the least affected gland. Autotrans­
plantation of this 50-1 00 mg tissue to the arm is favoured by 
many surgeons (201,202). If abnormal parathyroid tissue is
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not found then mediastinal exploration at a later date should 
be considered. Before this is carried out, detailed studies 
to localise the abnormal tissue should be carried out (203).
Treatment of asymptomatic hyperparathyroidism remains a 
matter of controversy (199,200,204-207). The natural history 
of symptomless hyperparathyroidism is often benign. Purnell 
et al (199) studied ‘141 asymptomatic patients with serum 
calcium concentrations below 2.75 mmol/1 and normal renal 
function. At follow-up, 12 years after the beginning of the 
study (208), 33 patients (23%) had been treated by operation 
because they no longer fulfilled the criteria: eight had
shown a rise in serum calcium concentration; six had 
developed active stone disease; four had developed bone 
disease; nine had psychological and various other factors and 
in six renal function had decreased. The study could not 
identify features predictive of a favourable outcome or 
factors predictive of serious and irreversible complications 
such as renal insufficiency or hypertension. Sampson et al 
(200) followed 68 patients with mild disease for a mean 
period of four and a half years (range 1-15 years) and failed 
to show any significant decline of renal function or 
worsening of hypercalcaemia. Only three patients from this 
series were referred for parathyroid surgery when serum cal­
cium concentration rose above 3 mmol/1, and another three 
developed a similar degree of hypercalcaemia. In this 
subgroup the rise in calcium was gradual and there were no 
instances of hypercalcaemic crises or symptoms. The authors 
suggested conservative management for patients over the age 
of 55 years with mild asymptomatic disease. Again, factors
predictive of severe disease were not identified..
Most patients with uncomplicated hyperparathyoidism are 
women past the menopause, a group already at high risk of 
bone loss which may be accelerated further by hyperpara­
thyroidism (45,209). Oestrogen treatment may ameliorate some 
consequences of hyperparathyroidism as well as preventing 
bone loss (207,21 0). Coe et al (207) reviewed available 
information about oestrogen treatment and concluded that 
evidence about the efficacy of this long-term medical treat­
ment compared with surgery was lacking.
Palmer et al (211) reported results of a 14-year follow- 
up of 172 persons identified in a health survey as having 
mild to moderate hypercalcaemia. A matched normocalcaemic 
group from the same population was followed up for 
comparison. The all-cause mortality was higher in the hyper­
calcaemic group, which was mainly due to higher mortality 
from diseases of the circulatory system. The hypercalcaemic 
group had significantly higher systolic and diastolic blood 
pressures and serum concentrations of urate. There was a 
tendency for serum concentrations of glucose and cholesterol 
to be higher but these differences were not significant. In 
this study PTH concentrations were unknown but it was assumed 
that the majority of patients had primary hyperpara­
thyroidism. There are other reports, describing better 
defined populations of patients with primary hyperpara­
thyroidism, which have confirmed Palmer's findings. Risk 
factors for cardiovascular disease were more frequent in 
patients with primary hyperparathyroidism than in controls 
(34,212-214) and association between hyperparathyroidism and
cerebrovascular or ischaemic heart disease has also been 
recorded (215,216).
Although such findings suggest that patients with hyper­
parathyroidism are at excess risk of cardiovascular disease, 
the reversibility of this risk by successful parathyroid 
surgery has not been established.
1.5.5. Hypertension and the parathyroid gland
An association between hypertension and hyperpara­
thyroidism was first described by Hellstrom et a.l (43) in 
1958. Hypertension which was defined as a blood pressure 
above 150/100 mmHg was present in 70 per cent of a series of 
105 patients with primary hyperparathyroidism. The degree of 
hypertension seemed to correlate with indices of renal 
impairment and in the majority of cases the impairment of 
renal function antedated the rise in blood pressure. In this 
early series, high blood pressure and its sequelae were 
responsible for about half of the mortality.
Surprisingly little progress has been made in under­
standing the nature of the association between hyperpara­
thyroidism and hypertension since the time of Hellstrom. The 
prevalence of hypertension has been variously estimated at 
10% to 60% of patients with primary hyperparathyroidism 
(34,45,192,212,213). Some of this variation reflects 
differences in methods of blood pressure measurement, diag­
nostic criteria and severity of hyperparathyroidism. Studies 
by Rosenthal and Roy (212) and Avioli (217) indicated that 
hyperparathyroidism is ten times more frequent in patients 
with otherwise "essential" hypertension than in the general
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population. The known but rare links between hyperpara­
thyroidism and other endocrinopathies, including phaeochromo- 
cytoma, Cushing's syndrome, primary- aldosteronism and acro­
megaly, do not explain the association (218).
Daniels and Goodman (34) in a large retrospective 
analysis of 120 patients with surgically proved primary 
hyperparathyroidism found that the mean serum calcium concen­
tration in the 49 patients with high blood pressures was 
almost identical to levels in the 71 patients with normal 
pressures. Significant correlations between serum con­
centrations of calcium and systolic or diastolic blood 
pressures were not found. Salahudeen et al' (1 95)rcame to the 
same view and also failed to find a fall in blood pressure 
after parathyroidectomy despite correction of hypercalcaemia 
and high parathyroid hormone levels.
It has been proposed that hypertension in hyperpara­
thyroidism results from increased activity of the renin- 
angiotensin system. Brinton et al (194) reported that plasma 
renin activity was elevated in four out of seven patients 
with hyperparathyroidism and hypertension but normal in five 
patients with normal blood pressures. Blood pressure and 
renin returned to normal following removal of parathyroid 
adenomas in three hypertensive patients with hyperpara­
thyroidism and were significantly improved in a fourth. How­
ever, calcium infusion does not stimulate renin secretion in 
vivo (37) and blood pressure does not fall after saralasin 
infusion (219). The most recent study (195) reported an 
increase in the mean ambulant renin above values in normo- 
tensive controls but not exceeding levels in patients with
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essential hypertension. These results and the absence of 
change after parathyroidectomy were interpreted as providing 
strong evidence against a role for renin or aldosterone in 
the hypertension of hyperparathyroidism.
Vlachakis et al (220) reported that patients with 
primary hyperparathyroidism had higher plasma concentrations 
of catecholamines and increased vascular reactivity to 
infused noradrenaline, but subsequent studies (221,222) have 
not confirmed this finding. Richards et al (222) could find 
no relationship between changes in catecholamines and changes 
in blood pressure or plasma levels of calcium after surgery. 
Despite the inherent problems in using concentrations of 
noradrenaline in venous plasma as an index of the activity of 
the sympathetic nervous system (223), the results of most 
studies do not support the contention that increased sym­
pathetic tone or responsiveness to noradrenaline are res­
ponsible for the high arterial pressure in primary hyper­
parathyroidism.
Is it then possible that renal damage is of importance 
in the pathogenesis of hypertension in hyperparathyroidism as 
originally suspected (43)? Later studies have questioned the 
relationship and found that hypertension was not invariably 
associated with impairment of renal function (212,213). 
Daniels and Goodman (34) could find no difference between the 
hypertensive and normotensive group in respect to mean values 
of serum creatinine, urea or creatinine clearance. The most 
recent study of the relationship between hypertension and 
renal dysfunction in primary hyperparathyroidism by 
Salahudeen et al (195) found a significant inverse relation­
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ship between blood pressure and Cr-EDTA clearance which 
persisted after successful surgical treatment.
Hypertension in patients with primary hyperpara­
thyroidism might be heterogeneous in origin. The mean age at 
the time of diagnosis of patients with hyperparathyroidism is 
about 50 years (34, 43,45). In the general Cauc.asian 
population at this age, the prevalence of essential hyper­
tension may be as high as 10-20%. Therefore, a number of 
patients with hyperparathyroidism and high blood pressure may 
have hypertension unrelated to hyperparathyroidism. Richards 
et al (222) have suggested that such coincidences might 
obscure true instances of hyperparathyroid specific hyper­
tension. This conclusion was based on a single observation of 
a pronounced fall in blood pressure in one of eight patients 
studied in detail before and after parathyroid surgery; a 
pressure fall that coincided with the largest falls in plasma 
concentrations of noradrenaline, renin and cortisol.
There have been conflicting reports on the overall blood 
pressure response to successful surgical treatment. Only one 
group has reported cure of hypertension in all cases (213). 
Daniels and Goodman (34) reviewed data from five studies on 
the effect of surgery on blood pressure. Blood pressure 
returned to normal postoperatively in 23 out of 83 patients 
studied (28%), which again raised the possibility that there 
is a subgroup who develop hypertension as a direct con­
sequence of hypercalcaemia. Worsening of hypertension after 
surgery has also been reported in some patients (43,187,224). 
The majority of studies have reported no change in blood 
pressure for groups of patients studied before and after
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parathyroidectomy (195,221 ,222,225,226). In addition Posen et 
al (226) found no difference in the prevalence of hyper­
tension in patients cured of hyperparathyroidism compared 
with those having no surgery or unsuccessful surgery.
A randomised prospective study of the value of surgery 
in hyperparathyroidism has not been performed. It is probably 
premature to advise that hypertension is an indication for 
surgery in uncomplicated mild hyperparathyroidism.
Section 6 - Left ventricular hypertrophy
1 .6.1 . Calcium and cell proliferation
Growth factors and other mitogens stimulate quiescent, 
nonproliferating cells in culture to re-enter the cell cycle 
and become committed to DNA synthesis. Although changes in 
intracellular pH and Ca^+ have been observed in many systems, 
it is not yet clear which of these ionic events are necessary 
steps in the pathway’ leading to DNA synthesis (227,228). The 
biochemical steps that drive quiescent cells out of Gq and 
through G-j to S phase are the key to understanding the mito- 
genic pathway (229). Evidence has been presented that early 
calcium increases associated with intracellular acidification 
are necessary steps for this transition (230-232). Subsequent 
mitogen-induced alkalinisation of the cell by activation of 
the Na+/H+ exchanger is probably independent of changes in 
intracellular Ca^+ (231).
It is interesting that contractile agonists and growth 
factors share many properties. Both have been reported to 
mobilize intracellular calcium (230,233), increase inositol 
trisphosphate turnover (230,234,235) and activate Na+/H+
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exchanger (231 ,232,236). Evidence has been presented that 
platelet derived growth factor (PDGF) induces not only cell 
proliferation but also vasoconstriction of smooth muscle 
cells (237). Similarly angiotensin II has been shown to 
stimulate growth in cultured vascular smooth muscle cells 
(238,232). Kawahara et al (239) presented evidence that 
angiotensin II can induce expression of the proto-oncogene c- 
fos through activation of protein kinase C and Ca 
mobilization in cultured rat aortic vascular smooth muscle 
cells. Similar processes have been described earlier for 
well-established growth factors such as platelet derived 
growth factor and epidermal growth factor (235). In line with 
these findings, calcium channel blockers such as nifedipine 
appear to slow the rate of PDGF-induced DNA synthesis and 
proliferation of smooth muscle cells (240).
It has been assumed that calcium influx in cardiac 
myocytes contributes to hypertrophy and it has been suspected 
that hypertrophic cardiomyopathy could be related to abnormal 
regulation of cytosolic calcium. In a Syrian hamster model of 
hereditary cardiomyopathy the concentration of calcium in 
myocytes was elevated (241), verapamil treatment prevented or 
delayed development of the condition (242 ,243) and the 
density of dihydropyridine binding sites was increased (2 44— 
246). Chronic administration of a calcium ionophore to preg­
nant rats has caused hypertrophy and disarray of myocardial 
myofilaments in the offsprings, histological findings similar 
to those found in hypertrophic cardiomyopathy (247).
Clinical trials have shown that diastolic dysfunction in 
hypertrophic cardiomyopathy in man is ameliorated by
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verapamil (248,249), which also relieves some of the symptoms 
(250). Increased numbers of dihydropyridine binding sites 
have been shown in the myocardium of affected patients (251). 
This increased density of voltage-sensitive calcium channels 
in the heart and the resultant abnormal calcium kinetics may 
explain the adverse effects of cardiac glycosides on 
ventricular function in this condition (252).
Much less is known about the more common form of cardiac 
hypertrophy that results from high blood pressure.
1.6.2. Left ventricular hypertrophy in essential hyper­
tension
Although a variety of factors modulate the rate or 
extent of myocardial hypertrophy, increased haemodynamic 
loading itself appears to be the primary factor responsible 
for compensatory hypertrophy of the pressure- or volume- 
overloaded heart in adults (253,254). In beating or quiescent 
isolated cardiac preparations, enhanced protein synthesis has 
been shown to result from increases in preload or afterload 
(255). Isolated rabbit papillary muscles have demonstrated a 
rapid increase in protein synthesis when stretched (256). 
Kent et al (257) showed that in isolated cardiac muscle of 
the ferret, stretch-induced activation of cation channels 
resulted in sodium influx, activation of the Na+, K+ -ATPase, 
and enhanced protein synthesis. The indirect effects of 
stretch-dependent sodium influx might include increased 
intracellular pH mediated by Na+/H+ exchanger, and increased 
intracellular calcium promoted by Na+/Ca^+ exchanger. All 
these processes might contribute to cellular growth. Hormonal
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stimulation by angiotensin II or noradrenaline acting through 
myocyte membrane receptors could also induce intracellular 
messengers and cause ventricular hypertrophy (258,259).
Studies with echocardiography have shown increases in 
left ventricular mass in young persons between 12 and 20 
years of age with only borderline elevations of arterial 
pressure (260). Mahoney et al (261) suggested that this 
increase in ventricular mass in childhood may predict sub­
sequent hypertension and its complications. Echocardiography 
has been especially useful in the study of left ventricular 
hypertrophy because it provides a wide range of information 
about anatomic variables (wall thickness, chamber dimension) 
as well as function of the ventricle during systole and 
diastole. Devereux and Reichek (262) have shown that left 
ventricular mass as determined by echocardiography in life is 
closely correlated with weight measured at postmortem 
examination. In adults with mild to moderate essential hyper­
tension the prevalence of left ventricular hypertrophy by 
echocardiography is an order of magnitude greater than the 
prevalence found using electrocardiography. It has become 
clear with more sensitive methods that as many as 40 to 50% 
of patients with relatively mild hypertension have increased 
ventricular mass (263). In most of these patients function of 
the left ventricle at rest and measured by echocardiogram or 
radionuclide cineangiogram is generally normal or even supra- 
normal (264,265).
Left ventricular- hypertrophy in hypertension has 
beneficial and detrimental effects (266,267). Several studies 
have shown increased incidence of ventricular dysrhythmias in
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patients with electrocardiographic left ventricular hyper­
trophy (268-270). Data from the Framingham study (270,271) 
and from the Glasgow Blood Pressure Clinic (272) have 
implicated left ventricular hypertrophy as an independent 
risk factor for cardiovascular mortality. A recent study from 
Glasgow by McLenachan et al (273,274) demonstrated that 
potentially serious ventricular arrhythmias were much more 
frequent in fifty treated hypertensive patients with electro­
cardiographic evidence of left ventricular hypertrophy than 
in the fifty hypertensive controls without E-CG abnormalities. 
Patients with echocardiographic (but not electrocardio­
graphic) evidence of left ventricular hypertrophy had more 
ventricular couplets and more runs of ventricular tachycardia 
of less than five complexes than normotensive controls. It 
appeared that increased ventricular mass predisposed to ven­
tricular ectopy.
Clinical and experimental studies on regression of left 
ventricular hypertrophy are of particular interest. Several 
questions have to be asked: Can established left ventricular 
hypertrophy be reversed by antihypertensive drug therapy? 
Does such reversal reduce the risk? Is it possible to 
distinguish lack of progression with time from true 
regression (275-277)? Recent experimental and.clinical 
evidence have demonstrated that some antihypertensive agents 
(eg, methyldopa, angiotensin converting enzyme inhibitors and 
most calcium antagonists) decrease left ventricular mass and 
wall thickness, whereas others (eg, diuretics, hydralazine, 
minoxidil and alpha-adrenergic receptor blockers) do not 
(278-281). It is not yet known if reducing cardiac size to
82
normal with pharmacological agents removes the risk 
associated with left ventricular hypertrophy. Studies in 
spontaneously hypertensive rats suggest that the proportion 
of collagen in the ventricular wall after regression of 
hypertrophy is still greater that normal (282). It is 
possible that antihypertensive therapy permits normal cardiac 
performance by inducing new forms of myocardial protein syn­
thesis (283,284).
1 .6.3. Left ventricular hypertrophy in endocrine hyper­
tension and primary hyperparathyroidism
Cardiac hypertrophy has been reported in most series of 
patients with acromegaly (285-288). Extreme cardiomegaly with 
heart weights between 1000-1300 g has been reported in the 
absence of other causes of cardiac enlargement such as hyper­
tension, valve disease and overt myocardial ischaemia 
(289,290). The. term "acromegalic heart disease" has been used 
to describe this condition (291). Generalised enlargement of 
organs and hypertrophy of tissues is a prominent feature of 
acromegaly, but detailed studies by Lie and Grossman (288) 
showed that enlargement of the heart was sometimes dis­
proportionate. Data from animal studies suggest that growth 
hormone excess causes increased DNA synthesis in cardiac 
myocytes and increased heart size. It is not certain whether 
this is a direct action of the hormone itself, an effect of 
somatomedin, or other mechanisms, such as ion fluxes across 
the cell membrane (292). A reversible action of growth hor­
mone on cardiac contractility has also been described in man 
(293) .
Using echocardiography, Mather et al (294) demonstrated
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increased left ventricular mass but normal values for indices 
of left ventricular function measured by non-invasive 
methods. They also suggested that cardiac mass might decrease 
with successful treatment. Further echocardiographic studies 
have established that the majority of patients with acro­
megalic heart disease have concentric left ventricular hyper­
trophy. Less commonly, patients with acromegaly met the 
criteria for asymmetric septal hypertrophy and only very few 
fulfilled the criteria for hypertrophic cardiomyopathy 
(294,295).
Cardiac arrh^ tihrriias, including ventricular tachycardia 
refractory to drug treatment, have been described in acro­
megaly and were not improved by treatment. The latter finding 
is compatible with the view that fibrous tissue infiltration 
is responsible for dysrhythmias but increased endogenous 
myocardial catecholamine levels and a disease of small intra­
mural vessels have also been implicated (291). The most 
recent data suggest that the impact of treatment of acro­
megaly upon acromegalic heart disease may be to slow its 
progression, but rarely to cause reversal (296).
In the case of phaeochromocytoma, it has been generally 
assumed that cardiac hypertrophy is the result of hyper­
tension. However, long-term noradrenaline infusion in the 
adult dog, insufficient to increase systemic blood pressure, 
causes left ventricular hypertrophy and the angiographic and 
haemodynamic features very similar to hypertrophic cardiomyo­
pathy (297). Little clinical evidence exists to suggest that 
the chronic catecholamine excess can cause hypertrophic 
cardiomyopathy, although this disorder has been described in
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a patient with phaeochromocytoma (298). In contrast to 
cardiac abnormalities of acromegaly, the majority of reports 
of phaeochromocytoma-induced cardiomyopathy note that physio- 
pathological effects are reversible after removal of the 
tumour (299).
Enlargement of the heart in hyperthyroidism has been 
recognised for many years but it is not yet clear if excess 
of thyroid hormone induces cardiac enlargement in human 
subjects without pre-existing cardiac disease. Cohen et al 
(300) have reported that thyroid hormone excess caused 
cardiac hypertrophy in mice. Conversely, thyroidectomy of 
young spontaneously hypertensive rats, during the prehyper­
tensive phase, prevents the subsequent development of hyper­
tension and causes a decrease in overall heart size and 
weight (301).
Thus in each of three disorders of endocrine function - 
growth hormone excess, catecholamine excess and thyroid 
hormone excess - cardiac hypertrophy may be the result of 
both abnormal wall stress and direct effects of growth 
factors. In each case hypertrophy may be preceded by changes 
in cellular calcium metabolism. The hypothesis that increased 
transmembrane calcium flux could be a common pathway in the 
pathogenesis of cardiac hypertrophy has been given some 
support by Symons et al (302) who studied cardiac hypertrophy 
in primary hyperparathyroidism. They described sixteen normo- 
tensive patients with primary hyperparathyroidism, of these 
five had hypertrophic cardiomyopathy, six had symmetric left 
ventricular hypertrophy and four had asymmetric septal hyper­
trophy. Only one patient in this group had no echocardio-
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graphic abnormalities. In a further group of six patients 
with hypercalcaemia due to causes other than hyperpara­
thyroidism, left ventricular wall thickness was normal in all 
cases. Moreover, parathyroid hormone concentration was raised 
in five of eighteen normocalcaemic patients with hypertrophic 
cardiomyopathy. The authors concluded that primary hyperpara­
thyroidism was almost invariably associated with left ven­
tricular hypertrophy in its various forms and that myocardial 
hypertrophy (including hypertrophic cardiomyopathy) was 
primarily associated with parathyroid hormone itself rather 
than with raised concentrations of extracellular calcium. As 
discussed previously (1.5.2.), parathyroid hormone has 
positive chronotropic effects on myocardial cells in culture, 
an action that is mimicked by calcium ionophores and blocked 
by verapamil (157). Parathyroid hormone has also been shown 
to have a positive inotropic effect on the rat heart at 
physiological concentrations (303). Since this action is also 
blocked by verapamil, it seems likely that it is related to 
the movement of calcium into the myocyte.
Clinical evidence for a relationship between parathyroid 
hormone and ventricular hypertrophy (302), together with 
experimental evidence that hypertrophy and disarray of the 
cardiac myocytes are produced by substances which disturb 
membrane stability, such as triac and calcium ionophore 
(247,304), add another dimension to the understanding of 
pathogenesis of idiopathic ventricular hypertrophy. There are 
no data on reversibility of left ventricular hypertrophy 
after surgical removal of parathyroid adenoma. Such clinical 
data might allow better understanding of the link between
parathyroid hormone and ventricular hypertrophy.
Section 7 - Aims of thesis
Two closely related studies were carried out.
Study I
1. A comparison of resting platelet cytosolic calcium 
[Ca^+]i levels in patients with untreated essential hyper­
tension and matched control subjects.
2. An assessment of [Ca^+]i responses to stimulation with 
vasoactive peptide arginine-vasopressin.
3. An examination-of the relationships between platelet- 
free calcium, blood pressure and left ventricular mass index.
4. Determination of platelet [Ca^+]i concentrations in a 
subgroup of hypertensive patients after eight weeks of anti­
hypertensive treatment.
5. Correlation of intracellular calcium levels with the 
activity of the renin-angiotensin system and plasma levels of 
catecholamines, atrial natriuretic peptide and parathyroid 
hormone.
Study II
1 . An assessment of the prevalence of high blood pressure 
in a group of patients with primary hyperparathyroidism.
2. Determination of left ventricular mass index by echo­
cardiography in the same group of patients and comparison of 
these indices with measurements in pair-matched controls 
(matched for sex, age and mean arterial pressure).
3. Measurements of resting free cytosolic calcium levels in 
platelets in primary hyperparathyroidism and of calcium
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transients after treatment with vasopressin.
4. An examination of the effects on platelet-free calcium 
of the renin-angiotensin system, catecholamines, phosphate, 
parathyroid hormone and atrial natriuretic peptide in this 
condition.
5. Effects of surgery on blood pressure, left ventricular 
mass, intracellular-free calcium and other biochemical 
variables.
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CHAPTER 2 - METHODS
Section 1 - Patients and study design
Eighty-three patients were studied and clinical details 
of these are described below:
2.1.1. Description of patients with essential hypertension 
and design of Study I
Patients with untreated essential hypertension (WHO 
grades I and II) and normal control subjects were studied. 
There were 30 patients with essential hypertension (17 males 
and 13 females) aged 25-67 years, and 30 normal control 
subjects (11 males and 19 females) aged 31-68 years. The 
majority of control subjects were either members of ancillary 
staff of the hospital or their relatives. Patients with 
essential hypertension had diastolic pressures above 95 mmHg 
(5 mins in sitting position) at two or three clinic visits. 
All subjects had normal serum concentrations of potassium and 
creatinine, and patients with secondary hypertension were 
excluded. The normal subjects had diastolic pressures less 
than 90 mmHg and no family history of hypertension in first 
degree relatives. All subjects gave informed consent and the 
protocol was approved by the Western Infirmary Ethical 
Committee.
On the morning of the study, subjects attended the 
department after fasting from 24.00 hours. Blood pressure was 
measured three times in subjects seated for 5 minutes, using 
a Hawksley random zero sphygmomanometer. An indwelling
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cannula was then inserted in a forearm vein and after 30 
minutes of recumbency 40 ml of blood was taken into sodium 
citrate for measurement of [Ca^+]i in platelets. Blood was 
also taken for measurements of serum concentrations of total 
calcium, ionized calcium and albumin, and plasma 
concentrations of parathyroid hormone, renin, angiotensin II, 
aldosterone, noradrenaline and atrial natriuretic peptide. 
Later the same morning two-dimensional and M-mode 
echocardiography were performed to estimate left ventricular 
mass. In thirteen patients all measurements were repeated 
after eight weeks of treatment with the calcium channel 
blocker verapamil (1 60-240 mg daily; n=6 ) or the beta- 
adrenoreceptor blocker atenolol (50-100 mg daily; n=7).
2.1.2. Clinical assessment of patients with primary hyper­
parathyroidism and design of Study II 
Twenty-three patients with primary hyperparathyroidism 
were studied (4 men and 19 women), aged -27-76 years. Five 
patients had a history of at least one episode of renal 
colic, two further patients had radiological evidence of 
parathyroid bone disease. In the remaining sixteen the diag­
nosis was made after routine calcium measurement. All 
patients had persistently raised serum calcium concentrations 
with parathyroid hormone (PTH) values that were 
inappropriately high. Seventeen out of twenty-three patients 
had parathyroidectomy. In twelve patients a single para­
thyroid adenoma was removed and in four others the histology 
of the excised glands showed evidence of hyperplasia. In one 
patient an adenoma was not found during the first neck
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exploration and a mediastinal location was suspected. Three 
patients declined to have surgery and in three others surgery 
has been deferred. The first comparison was made with a group 
of thirty normal control subjects described in 2.1.1. Because 
2 0% of patients with primary hyperparathyroidism had high 
blood pressure (WHO grade I and II) a further control .group 
was defined which allowed subjects to be matched for blood 
pressure. Each patient with primary hyperparathyroidism was 
matched for age, sex and mean arterial pressure (MAP) with a 
normal control subject or a subject from a group of thirty 
untreated hypertensive patients described in 2.1.1. The age, 
sex and blood pressure-matched control group consisted of 
twenty-three subjects (4 men and 19 women), aged 34 to 65 
years. All subjects were on no medication and had normal 
serum concentrations of potassium and creatinine. The study 
protocol was approved by the Western Infirmary Ethical 
Committee and the subjects gave informed consent.
The protocol of this study was identical to the one 
described above (2.1.1). In twelve patients all measurements 
were repeated six to twelve months after parathyroidectomy.
Section 2 - Laboratory methods
2.2.1. Free cytosolic calcium concentration in platelets
The cytosolic free calcium concentration [Ca^+]i in 
platelets was measured using Quin 2; the method is a 
modification of the method first described by Tsien for 
lymphocytes (94). Platelet rich plasma was prepared by 
centrifuging citrated whole blood (1 ml 3.9 per cent sodium 
citrate and 9 ml blood) at 250 g for 5 min at room
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temperature. Platelet rich plasma was then incubated for 30
min at 37^C with 10 yimol/1 Quin 2 acetoxymethylester (Quin
2/AM, Lancaster Synthesis Ltd, Morecambe, Lancs. UK).
Ethyleneglycolbis (aminoethylether) tetra-acetate (EGTA 5
mmol/1; Fluka) was added and platelet-rich plasma then
centrifuged at 250 g for 10 min. The supernatant was removed
and the pellet resuspended in calcium-poor medium containing:
140 mmol/1 NaCl, 1 mmol/1 KC1, 1 mmol/1 MgC^; 10. mmol/1
glucose and 20 mmol/1 4-(2-hydroxyethyl)-1-piperazine-ethane
sulphonic acid, titrated to pH 7.3 at 37^C. The cells in the
T Hsuspension were counted in a Coulter Counter (Technicon H-1 
system) and the concentration of cells was adjusted to 1.5 - 
2x10®/ml. Calcium in the medium was restored to 1 mmol/1 by 
adding calcium chloride. Fluorescence was measured with a 
Perkin-Elmer LS-3B spectrofluorometer at 339 nm excitation 
and 492 nm emission wavelengths. The calibration of intra­
cellular fluorescence as a function of [Ca^+]i was performed 
as previously described (94) and [Ca^+]i was calculated from 
the equation:
[Ca2+]i = 115 (F-F min/F max-F) 
where 115 represents the equilibrium dissociation constant 
(nmol/1) and F the fluorescence of the intact cell sus­
pension. Fmax represents the maximum fluorescence obtained 
after the cells were solubilized with digitonin (50 ^imol/1), 
(Sigma). Fm^n represents the minimal fluorescence obtained in 
the presence of 2 mmol/1 MnC^. Manganese displaces calcium 
from the chelator and gives a very low fluorescence signal. 
The leakage of Quin 2, examined by adding 2 mmol/1 MnCl2 to 
loaded platelets, after washing and resuspending in platelet
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buffer was minimal (range 0.25 - 1 per cent in 2 hours). 
There was no difference between platelets from normotensive 
and hypertensive subjects. The intra-assay variability as 
measured by five experiments with 10-15 separate [Ca^+]i 
estimations on the same preparation of platelet rich plasma, 
was less than 10% and the day-to-day intrasubject variation, 
as measured by 21 estimations of [Ca^+]i within 10 days, was 
10.%. [Ca^+]i results are expressed as the mean of triplicate
measurements.
2.2.2., Effects of stimulation with arginine-vasopressin 
(AVP)
The response of platelet [Ca^+]i to AVP ([Arg®] vaso­
pressin; Sigma) was measured. Studies of the concentration- 
response relationship indicated that the response was maximal 
at an AVP concentration of 1 jumol/1. Accordingly, this con­
centration was used in the comparison of responsiveness 
measured in cells from hypertensive subjects, patients with 
primary hyperparathyroidism and normal controls. This 
response was measured in the presence of extracellular cal­
cium (1 mmol/1 ) and when extracellular calcium was reduced to 
negligible concentrations (10-20 nmol/1) by adding 5 mmol/1 
EGTA.
2.2.3. Other biochemical variables
Ionized calcium concentrations corrected to pH 7.4 were 
measured using a Radiometer ICA-1 ionized calcium analyser as 
previously described (12). Total calcium and protein were 
measured on a SMAC-1 (Technician Instruments Corporation, 
Basingstoke, UK) according to the manufacturer's protocol.
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Total serum calcium values were corrected for albumin con­
centration using the formula:
Calcium corrected = measured calcium + 0.02 (40 - serum
albumin)
Serum parathyroid hormone (PTH) was measured with a two site 
immunometric assay for intact (1-84) human parathyroid hor­
mone using monoclonal antibodies (152). Plasma active renin 
(305), angiotensin II (306), aldosterone (307) and atrial 
natriuretic peptide (308) were measured by radioimmunoassay 
and catecholamines by a radioenzymatic method (309).
Section 3 - Left ventricular mass
2.3.1,. Two dimensional and M-mode echocardiography
Echocardiography was carried out using a Hewlett-Packard 
Ultrasound Unit with a 2.5 - MHz transducer. All echocardio­
grams were recorded by one person (AFD). Patients were 
studied in the left decubitus position with the transducer on 
the third to fifth intercostal space. Simultaneous 
visualisation of interventricular septal thickness (IVST), 
left ventricular internal dimension (LVID) and posterior wall 
thickness (PWT) was sought, just below the tips of the mitral 
valve leaflets. Echocardiograms which showed unambiguous high 
quality images of IVST, LVID and PWT with continuous inter­
face lines were deemed technically adequate for study. Echo­
cardiograms of two out of thirty hypertensive subjects (6%), 
four out of thirty control subjects (13%), two out of twenty- 
three hyperparathyroid patients (9%) and one out of twenty- 
three controls matched for age/sex/MAP (4%) were not of
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adequate quality and were excluded from further analysis. It 
has been previously established that it is not possible to 
obtain technically satisfactory echocardiograms in up to 2 0% 
of hypertensive patients (310).
M-mode recordings were made on 6 -inch (15 cm) light- 
sensitive paper with a paper speed of 50 mm/sec. The ECG was 
recorded simultaneously. The two-dimensional echocardiogram 
image was used to position the cursor appropriately. M-mode 
recordings were coded and analysed without the knowledge of 
the classification into patients and controls. Analysis was 
performed using a digitising tablet (Kontron Ltd) and a 
microcomputer. Left ventricular posterior wall thickness, 
interventricular septal thickness and left ventricular 
diastolic diameter were all measured distal to the tips of 
the mitral valve leaflets and at the peak of the R wave on 
the electrocardiogram. The measurement points were selected 
using the Penn convention (262). This method excludes the 
thickness of endocardial echoes from measurements of IVST and 
PWT and includes the thickness of endocardial echoes to 
measurements of LVID, as shown on Figure 7. Measurements were 
made over three consecutive cardiac cycles, and mean values 
were calculated. Figure 8 shows an M-mode recording from a 
normal subject.
2.3.2. Calculation of left ventricular mass
The method used in this analysis was the cube formula 
incorporating Penn convention as described by Devereux and 
Reichek (262). The formula is as follows:
LV mass '(g) = 1.04 [ (IVST+PWT+LVID) 3 - (LVID)3] - 13.6 
where:
95
IVST { Ventricular
Septum
LVID
Chordae
,Tendineae
Endocardium
LV Posterior 
Wall
Epicardium
PWT
Figure 7 Schematic representation of M-mode echocardiographic 
left ventricular (LV) anatomic measurements (Penn 
convention).
Measurements are made at the peak of the electrocardiographic 
R wave with exclusion of endocardioal interface thickness 
from measurements of ventricular septal and posterior LV wall 
thickness. IVST = septal thickness, PWT = posterior wall 
thickness and LVID = left ventricular internal diameter. 
Modified from reference 262.
, I .... I .... I .... I .... I .... I .... I .... I .... I .... I .... I
IVS
PW
Figure 8
M-mode echocardiogram of a normal subject.
IVST = septal thickness excluding right and left ventricular 
endocardial echoes.
PWT = posterior wall thickness excluding endocardial and 
epicardial echoes.
LVID - left ventricular internal diameter including the 
septal and posterior wall endocardial echoes.
This method has been validated by comparison with anatomical 
left ventricular mass measurements (262). Measurements of 
left ventricular mass were then divided by body surface area 
to obtain left ventricular mass index (310).
LV mass (g)
LV mass index (g/m2) = ------- ----
BSA (m2)
2.3.3. Reproducibility of echocardiographic measurements
The reproducibility of echocardiographic measurements in 
a single subject was calculated by measuring left ventricular 
mass on ten occasions in the same healthy volunteer. The 
coefficient of variation was 2.9%. Interobserver variability 
of 4% was determined from calculations by two observers of 
left ventricular mass in 25 of the recordings.
Section 4 - Statistical analysis
2.4.1. Power calculation
It was estimated that twenty normal subjects and twenty 
hypertensive patients would be needed to give a 90% power to 
detect a difference in [Ca2+]i of 50 nmol/1 at the 
significance level of 5%. For this calculation it was assumed 
that the difference in [Ca2+]i between hypertensive and 
normotensive subjects was in the range described by Erne et
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al (105).
2.4.2. Statistical methods
Comparisons be tween groups were performed using Mann- 
Whitney U-test. Normally distributed variables are expressed 
as means, standard errors of mean and 95% confidence 
intervals. Other results are given as medians with 95% 
confidence intervals. Comparison of results before and after 
parathyroidectomy were made using Wilcoxon signed ranks test 
and correlations were calculated by the rank Spearman method. 
P values less than 0.05 were regarded as significant.
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CHAPTER 3 - RESULTS 
This chapter will be devided into two parts:
Section 1 - Results of Study I
3.1.1. Characteristics of patients with essential hyper­
tension and control subjects 
Clinical details are summarised in Table 2. The groups 
were well matched for age, body weight and height but there 
was a slight predominance of men in the hypertensive group. 
As expected, mean values of systolic and diastolic pressures 
were significantly higher in the hypertensive group. Left 
ventricular mass index was also significantly higher in the 
hypertensive patients (95% Cl -55.6 to -21.8, P<0.001; Table 
2 ).
Serum concentrations of total and ionized calcium, 
plasma concentrations of parathyroid hormone, renin, 
angiotensin II, aldosterone, catecholamines and atrial 
natriuretic peptide are summarised in Table 3. Serum 
concentrations of total and ionized calcium were similar in 
the two groups. Plasma concentrations of parathyroid hormone 
were significantly higher in the hypertensive group (95% Cl - 
1 to -0.1, P = 0.013; Table 3). Six of the hypertensive 
patients had low-renin essential hypertension as previously 
defined (311). Plasma concentrations of active renin, 
angiotensin II, aldosterone, atrial natriuretic peptide and 
adrenaline were similar in hypertensive patients and normal 
controls. Plasma noradrenaline concentrations were 
significantly higher in hypertensive subjects (95% Cl -1.3 to 
-0.1, P=0.02; Table 3).
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3.1.2. Resting and stimulated free cytosolic calcium in
platelets [Ca^li 
The median [Ca^+]i in platelets in the hypertensive 
group was 93.3 nmol/1 and values were not significantly 
different from those in the control group (87.8 nmol/1, 95% 
Cl -12 to 5.8, P=0.5; Figure 9). Correlations between
platelet [Ca^+]i and.age, blood pressure, left ventricular 
mass index, serum concentration of calcium (total and 
ionized) or plasma concentration of renin were not 
significant. Median concentrations of [Ca^+]i in men and 
women in the control group were 92 nmol/1 and 91 nmol/1, 
respectively (95% Cl -11.7 to 11.1; P = 0.62).
Preliminary experiments established that a concentration 
1 umol/1 of AVP caused the maximum increase of cytosolic free 
calcium concentrations (Figure 10). AVP caused an increase in 
[Ca^+]i in all subjects studied and representative transients 
obtained in platelet suspensions from hypertensive and con­
trol subjects at various extracellular calcium concentrations 
are shown on figure 11. In the presence of extracellular 
calcium (1 mmol/1) the [Ca^+]i increase was significantly 
higher in control subjects than in the hypertensive patients. 
In the presence of EGTA (5 mmol/1) and without added calcium, 
AVP at the same concentration caused much smaller - increases 
in [Ca^+]i and there was then no difference between hyper­
tensive and control subjects (Figure 12).
3.1.3. Effects of blood pressure lowering treatment
In the subgroup of patients who were treated for eight
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Figure 9
Scatter diagram of the [Ca ]j in 30 hypertensive patients 
( • )  and 30 control subjects (o) .  Horizontal lines 
represent median values; 95% Cl -12 to 5.8, P = 0.5.
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2 5 0 -
Log [AVP] (mol/1)
Figure 10
Concentration - response relationship between AVP and 
platelet [Ca2+]j in cells from normal subjects in the 
presence of extracellular calcium (1 mmol/1). Results 
are means of five experiments(+ SEM).
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Figure 11
Effect of AVP on tCa2+]j in the presence (upper panel) and 
absence (lower panel) of external Ca2 + . AVP 10 mol/1 was 
added as indicated. The appropriate calibration scales for
[Ca2+ ]j are shown on the left side of each fluorescence trace
Gaps in the recording show periods of addition.
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Figure 12
Comparison between the AVP-induced increase in [Ca2+]< in 
hypertensive patients ( ■ )  and control subjects ( □ ) .  
Upper panel - in the presence of 1mmol/l external Ca2+ 
(95% C M 38 to 846, P = 0.004). Lower panel - in the 
absence of external Ca2+ (95% Cl - 17.3 to 13, P = 0.82).
weeks with either verapamil (n=6 ) or atenolol (n=7), both 
systolic and diastolic pressures decreased significantly but 
this blood pressure-lowering effect did not result in changes 
in basal [Ca^+]i (Table 4). However, there was a significant 
positive correlation between changes of systolic pressure and 
changes in platelets [Ca^+]i for the whole group (r=0.75, 
p<0.01; Figure 13a). A similar but less significant positive 
correlation was found between changes of diastolic pressure 
and changes in platelet [Ca^+]i, (r = 0.51 , 0.05 < P <0.1;
Figure 13b). The AVP-induced increase in platelet [Ca^+]i was 
not affected by drug treatment (948 vs 1052 nmol/1, P=0.6). 
In the absence of extracellular calcium the [Ca^+ ]i 
transients were almost 1 0-fold lower, but drug treatment 
again had no effect: 132 nmol/1 and 136 nmol/1 before and 
after treatment, respectively.
Section 2 - Results of Study II
3.2.1. Characteristics of patients with primary hyperpara­
thyroidism and control subjects and blood pressure 
results
Clinical details of 23 patients with primary hyperpara­
thyroidism are summarised in Table 5. Two patients had 
asymptomatic bone disease with radiological evidence of 
subperiosteal bone resorption in the phalanges in one and a 
brown tumour in the second patient. Five patients gave a 
history of at least one episode of renal colic. Four out of 
23 patients had a family history of hypertension in at least 
one first degree relative (Table 5).
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TABLE 4
Effects of antihypertensive treatment on [Ca^+]i and blood 
pressure- Results from patients treated with verapamil and 
atenolol have been combined; n = 13 •
Variable Value
[Ca2+]i
Before treatment (nmol/1) 102
After 8 weeks of treatment (nmol/1) 95
95% confidence interval -13. 2.5
P 0.14
Systolic blood pressure
Before treatment (mmHg) 169
After 8 weeks treatment (mmHg) 152
95% confidence interval -29.5, -3.0
P 0.013
Diastolic blood pressure
Before treatment (mmHg) 109
After 8 weeks treatment (mmHg) 91
95% confidence interval -25.0, -9.5
P 0.002
Results are given as medians and 95% confidence intervals.
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Change in [Ca^ ]j 
(nmol/1)
-15-
-30-60. 0 15
Change in systolic blood pressure (mmHg)
Change in [Caz ]j 
(nmol/1)
-15-
-21 7
Change in diastolic blood pressure (mmHg)
Figure 13
Correlations between changes in [Ca2+]j and blood pressure 
observed in hypertensive patients (n = 13) during drug treatment. 
Results with verapamil and atenolol have been combined.
(a) Systolic blood pressure (r = 0.75, PO.01).
(b) Diastolic blood pressure (r = 0.51, 0.05 <P<0.01).
d d d
•H •H *H
0 0 0 0
> 0 d d d
•H CP rH rH r-4 d d d d d d d
4-> G 0* Cb a g g g g g g g
d *h u S-l u 0 0 0 0 0 0 0
U 13 0 0 0 C3 G C3 C3 G C3 G
0 G a a cb 0 0 0 0 0 0 0
Cb *H >i >i >i 13 13 13 13 13 13 13
O H cn 33 33 < < < < < < i < 1 1
-
T— vo r- as CP t-- oo CN 00 CP • 00
33 \ • • • • • • • • • • • • •
EH D H1 00 00 vo 00 00 r— in 00 T— CN VOd, ^ t— T— T—
in
H
I
s
w•H
•H
0
M
>h
A4J
d
M
d
a
M
0)
a
>i
A
>H
U
d
5 •H
ua,
6  4J ■H 
£
W
JJ
a
0)•H
•P
d
a
ro
CN
G•H
in
tr
G
•H
TJ
G■H
M-l
H
d
0■H
G
•H
H
U
g u 
G O ^
•H H-) rH
o \
rH U  I—I
d 0 o o -P e 
u6 0 -
G u H 1 O CN in CP I"- O'- o in H 1 uo oo
54 U A VO 00 00 o vo VO O vo r - r - VO n - in
0 0 r-H • • • • • • • • • • • • •
CQ U d CN CN CN 00 CN CN 00 CN CN CN CN CN CN
M-)
0
G 
O 
*H
0 
C 
> 1  0  
>1 U 4J 
rH O U  
•rH 4-1 0
g 0 a
d *H >i 
fo J3 JG
0 
S-l 2 —* 
13 0 CP 
O 0 33 
O 0 g
rH S-! g
CQ PH —
0
g
O
4->
a
g
m
G
CP
•H
CQ
CQ 03
X
0
CQ
0
0 U CP >i 
< ~
0
0
d
u
VO CN
r- <p
r -
r -  oo
^  L O  o  r-
oo cn m  in
o
•H
rH
o
o
rH
d
G
0
P3
VO
CP r - VO T—
00 oo oo
vo r" o 00 CO
N* T“ T— r—
t— r— T— T— T-
P4
o
•H
rH
o
o
rH
d
c
0
«
pH pH
CN
VO O"31 t-
m
r-
t— cp
CN
Cn pH Ph pH
c p o o o o  c N H i o o i n T - o o o o c N r ' ~ ( P  
o o i n . v o v o v o o o ' ^ c o o o ' t f i n c N i n
cn oo . ^  i n vo oo as CN 00
104
rH d
d •H
2 0
•H d
d d 4-> d d d d rH
g g 0 g g g g a
0 0 d 0 0 0 0 u
2 2 •H 2 2 2 2 0
0 0 13 0 0 0 0 Cb
T3 13 0 13 U 13 13 rH
< < I S d C  I i < < ffi
o ro o o CN in o o 00 VO
• • • t • • • • • •
CP in T— CN in vo T— in
CN T— . T— CN
ro 00 00 O VO cn O r^ CN CN
r» m VO 00 VO [•" as r - in co
• • • • • • 9 • • •
CN CN CN CN CN CN CN CN ro CN
2
SO
G
M
G
I + + I D I + I I  I
co
VO in r ^ vo o VO o in oo
00 00 00 CP n- oo r— 00 00
■—. — \ '■'s.
00 CN ro CP ro CN o
VO r - CN CN ro T— ro in
*” T_ T_ T” r— v— CN r_ T”
o U U
•H •H 1 •rH i
rH r-H d i—1 d
0 0 u 0 Sh
o 0 d  13 0 o d  13 0
Cb *H 0 Cb *H 0
rH rH U 0 d rH U 0 d
d d 0  Ih 0 0 d 0  u 0 0
2 2 Cb > , 2 0 2 Cb > , 2 0
0 0 > i 2  0 •H 0 >iJG 0 •H
& i i l 1 « ffi 4-1 U 03 S3 4-» 43 T5
13022
•H
4-12O
U
in
0I-!
JQ
dEh
p4 Cn Cn S
CN CN 00 N1
vo vo ^  r -
Cn Cn Cn
vo O
vo r-*
^  in  vo r -  co <p o
Cn Cn
in  n * 
vo N 1
t- CN
CN CN
r -
ro
CN
105
Patients with primary hyperparathyroidism were compared 
with a group of 30 normotensive controls who were matched for 
age and body weight and with a second control group which was 
further matched for sex and blood pressure (Table 6 ). The 
systolic, diastolic and mean arterial pressures were 
significantly higher in patients with primary hyperpara­
thyroidism than in normotensive controls (Table 6 , Figure 14) 
and five out of twenty-three patients (2 2%) were hypertensive 
using WHO criteria (grades I and II). In one patient there 
was a fall of 32 mmHg in systolic blood pressure eight months 
after parathyroidectomy, but there was no significant changes 
in blood pressure in the group as a whole (Figure 15).
3.2.2. Left ventricular mass index
Left ventricular (LV) mass index was significantly 
higher in the primary hyperparathyroid group than in either 
control group (Table 6, Figure 16) but did not correlate with 
platelet calcium, extracellular calcium, parathyroid hormone 
or blood pressure. However, there was a significant 
correlation between systolic blood pressure and left 
ventricular mass in the age, sex and blood pressure-matched 
control group (r=0.48, P<0.05, Figure 17a). A similar but
less significant positive correlation was found in the same 
group between mean arterial pressure (MAP) and LV mass index 
(r=0.4, P<0.1; Figure 17b).
In twelve patients in whom LV mass index was measured 
six to twelve months after surgery, parathyroidectomy was 
associated with a small reduction in mass index of the left 
ventricle but this change was not significant (P=0.1 , Figure 
16).
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Mean arterial 
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Figure 14
Scatter diagram of the mean arterial pressure in 23 patients 
with primary hyperparathyroidism (•) and 30 control subjects 
(o).  Horizontal lines represent median values; 95% Cl 
-15.3 to -3, P = 0.003.
Blood pressure 
(mmHg) 200-
Systolic
100-
Diastolic
Before After
surgery surgery
Figure 15
Blood pressure (systolic and diastolic) in 12 patients before 
(•) and after (o) parathyroidectomy. For systolic blood 
pressure: A =-3.3, 95% Cl -10 to 3.5, P = 0.5. For 
diastolic blood pressure: A = +2.6, 95% Cl -2 to 8, P = 0.33.
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Figure 16 Left ventricular mass index
Left panel - comparison of LV mass index in 21 patients with 
primary hyperparathyroidism and 21 age, sex and mean arterial 
pressure matched controls; 95% Cl -36.1 to -3.1, P = 0.03.
Right panel - comparison of LV mass index in 12 patients 
before and after parathyroidectomy; A  =22.8, 95% Cl -46.5 
to 2.5, P = 0.1.
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Figure 17
Correlations between blood pressure and LV mass index observed 
in matched control subjects.
(a) Systolic blood pressure (r=0.48, P<0.05).
(b) Mean arterial pressure (r=0.4CL 0.05<P<0.1).
3.2.3. Extracellular calcium, phosphate and parathyroid
hormone
As expected, serum concentrations of calcium corrected 
for albumin, ionized calcium and plasma concentrations of 
parathyroid hormone were higher and serum concentrations of 
phosphate significantly lower in patients with primary 
hyperparathyroidism (Table 7, Figure 18). After parathyroid 
surgery these abnormal levels were corrected (Table 8 ).
3.2.4. Resting and stimulated free cytosolic calcium in 
platelets [Ca^+]i; effects of parathyroidectomy____
The median concentration of free cytosolic calcium in 
platelets in the hyperparathyroid group was significantly 
lower than in the blood pressure matched control group: 81.5
nmol/1 and 93 nmol/1 respectively, 95% Cl 0.1 to 20.1, P<0.05 
(Figure 19). There was an inverse correlation between [Ca^+]i 
and diastolic blood pressure in the hyperparathyroid group 
but not in the control group (r = -0.4 6 , P<0.05; Figure 20). In 
eleven patients in whom [Ca^+]i was measured before and after 
successful parathyroidectomy there was a tendency of [Ca^+]i 
to increase at six to twelve months after surgery (A  =8.9 r 
P=0.068, Figure 19).
Representative calcium transients in response to vaso­
pressin are shown on Figure 21. The median concentrations of 
[Ca^+]i in response to AVP (1 ^umol/1) were 136 nmol/1 in the 
primary hyperparathyroid group and 1248 nmol/1 in control 
subjects (95% Cl 761 to 1551, P<0.001; Figure 22). This 
difference persisted when EGTA was added to the medium but 
was then much smaller: 110 nmol/1 and 137 nmol/1 in hyper-
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Ca
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Figure 18
Scatter diagrams of the extracellular calcium and parathyroid 
hormone in 23 hyperparathyroid patients ( • )  and 23 matched 
control subjects (o).
(a) Calcium corrected for albumin - 95% Cl -0.5 to -0.37, 
P<0.001.
(b) Ionized calcium (Ca2+) - 95% Cl -0.38 to -0.27, P<0.001.
(c) Parathyroid hormone (PTH) - 95% Cl -6.9 to -3.1, P<0.001.
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Figure 19
Left panel - scatter diagram of the [Ca2+li in hyperparathyroid 
patients (•) and matched controls (o). Horizontal lines 
represent median values. There were 22 estimations in the 
hyperparathyroid group, in one patient measurements were 
technically, unsatisfactory (95% Cl 0.1 to 20.1, P<0.05).
Right panel - [Ca2+]t for individual patients before ( ■ ) and 
after ( □ ) parathyroidectomy. Horizontal lines represent 
median values (n = 11, 95% Cl -2.1 to 20.1, P=0.068).
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Figure 20
Relationship between platelet calcium [Ca2 + ]j and diastolic 
blood pressure in the hyperparathyroid group (n=22, r=-0.46, 
P<0.05).
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Figure 21
Effect of AVP on [Ca2+]j in hyperparathyroid patients (upper 
panel) and matched controls (lower panel). AVP 10~° mol/1 
was added as indicated. Extracellular calcium was immol/1. 
The appropriate calibration scales for [Ca2+]j are shown on 
the left side of each fluorescence trace. Gaps in the 
recording show periods of addition.
Figure 22
Comparison between the AVP-induced increase in [Ca2 +L  in 
patients with primary hyperparathyroidism ( □ )  and matched 
control subjects (El).
Left panel - in the presence of lmmol/1 external Ca2+ (95% 
Cl 761 to 1551, P<0.001). Right panel - in the absence of 
external Ca2+ (95% Cl 12 to 44, P=0.002).
parathyroid and control groups respectively (95% Cl 12 to 44, 
P=0.002; Figure 22).
3.2.5. Renin-angiotensin system, catecholamines and atrial 
natriuretic peptide; effects of parathyroidectomy 
Plasma concentrations of active renin, angiotensin II, 
aldosterone, adrenaline, noradrenaline and atrial natriuretic 
peptide were not different between the groups (Table 7, 
Figures 23, 24 and 25). A weak negative correlation was
observed between plasma concentrations of active renin and 
atrial natriuretic peptide in the hyperparathyroid group (r=- 
0.4; 0.05 < P<0.1; Figure 26). After parathyroidectomy there 
was a small but significant increase in plasma concentration 
of aldosterone. Otherwise plasma concentrations of active 
renin, angiotensin II, catecholamines or atrial natriuretic 
peptide were similar before and after surgery (Table 8 ).
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Figure 23
Scatter diagram of plasma renin concentrations (PRC) and 
plasma concentrations of angiotensin II (pAngll) in 
hyperparathyroid patients ( • )  and matched control subjects 
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Figure 24
Scatter diagram of plasma concentrations of noradrenaline 
(pNoradr.) and adrenaline (pAdr.). in hyperparathyroid 
patients ( • )  and matched control subjects (o) .
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Figure 25
Scatter diagram of plasma concentrations of atrial 
natriuretic peptide (pANP) and aldosterone (pAldo) in 
hyperparathyroid patients ( • )  and matched control subjects
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Figure 26
Relationship between atrial natriuretic peotide (ANP) and 
plasma renin concentration (PRC) in the hyperparathyroid 
group (n = 22, r=-0.4, 0.05<P<0.1).
CHAPTER 4 - DISCUSSION
Section 1 - Extracellular calcium, parathyroid hormone and 
plasma catecholamines in essential hypertension
4.1.1. Extracellular calcium
As found in a previous study from our laboratory (1 2), 
serum concentrations of total and ionized calcium did not 
differ between untreated hypertensive patients and matched 
control subjects. These results do not confirm the original 
observation by McCarron (6 ), but are consistent with sub­
sequent studies (5,8,18,19). Tillman and Semple (12) reviewed 
possible confounding factors in ionized calcium measurements 
such as posture, ambulation, blood pH and diurnal variation. 
In contrast to some earlier studies, sampling conditions were 
strictly st-andarized with the blood collected anaerobically 
without stasis or forearm exercise and at the same time of 
the day. Patients had blood sampled via an indwelling cannula 
rather than by the direct venepuncture (6,8,18,19), a 
procedure that may be less likely to provoke hyper­
ventilation. Mild respiratory alkalosis from overbreathing 
reduces serum concentration of calcium ions. It is noteworthy 
that earlier studies did not consider effects of treatment 
with some patients on thiazide diuretics which increase serum 
concentrations of ionized calcium (312,313).
4.1.2. Enhanced parathyroid gland activity secondary to 
hypercalciuria
Increased urinary calcium excretion, accompanied by 
enhanced parathyroid gland activity, has been reported in
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hypertensive subjects (5,11,12). Strazzullo et al (5) have 
argued that this hypercalciuria is related to a defect in 
renal tubular calcium handling in essential hypertension, but 
reported similar levels of serum total and ionized calcium 
concentrations in patients and controls. It appeared that the 
enhanced urinary calcium output in essential hypertension was 
not dependent on an increased filtered load of calcium, but 
likely to be accounted for by a primary renal defect.
In the current study urinary calcium excretion was not 
measured but, as in other studies (5,11,20), plasma PTH 
concentrations were slightly increased in patients with 
essential hypertension. Parathyroid overactivity may be a 
compensatory response to a proximal tubular calcium leak to 
increase calcium reabsorption in the distal part of the 
nephron (5). The process of calcium reabsorption is dependent 
on passive entry of calcium from the tubular lumen into the 
cell interior down its electromechanical gradient and active 
extrusion at the contraluminal surface (314). Although cal­
cium ATP-ase activity has not been measured in renal tissue, 
a reduced rate of calcium efflux has been found in vascular 
smooth muscle from SHR (315) and in red blood cells of hyper­
tensive subjects (316). Such a defect may reflect a wide­
spread abnormality of transmembrane calcium transport in 
hypertension that has been proposed by several groups of 
investigators (62,76,31 7,31 8 ). A similar defect in renal 
tubular cells could be the mechanism that determines the 
hypercalciuria.
The possible effect of increased PTH levels on blood 
pressure has also been considered. The development of
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hypertension in rats with genetic or DOCA-induced 
hypertension is attenuated by parathyroidectomy (319). 
Grobbee et al (20) have reported increased plasma 
concentrations of intact (1-84) parathyroid hormone in young 
subjects with mildly raised blood pressures and a significant 
relationship between the two variables. The hypothesis that 
enhanced parathyroid gland activity is implicated in the 
development of essential hypertension has not been disproved.
4.1.3. The interrelationship of plasma catecholamines and 
parathyroid gland activity
The sympathetic nervous system may affect parathyroid 
gland activity (22). Grobbee et al observed increased 
concentrations of noradrenaline, adrenaline, and dopamine in 
a group of young subjects with mild hypertension (23) 
selected from the same population of patients described in 
reference (20). Plasma concentrations of noradrenaline but 
not adrenaline were significantly higher in my group of 
patients with essential hypertension than in normotensive 
controls, but patients and controls were slightly older than 
in the previous study. Extrapolations from venous 
noradrenaline levels to activity of the sympathetic system 
should be done cautiously((223,344),but it does seem that this 
small group of patients with essential hypertension had 
slightly increased plasma concentrations of noradrenaline and 
parathyroid hormone.
Direct application of PTH to cardiac myocytes increases 
calcium uptake (157) but its action on vascular smooth 
muscle cells is less well defined. Nickols (167) demonstrated 
that PTH relaxes aortic strips and that cAMP may be involved
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in the mechanism of PTH action in vascular tissue. In acute 
experiments it is clear that PTH acts as a vasodilator and 
lowers arterial pressure (158-160). Saglikes et al (159) have 
shown that the pressor effects produced by bolus injections 
of noradrenaline and angiotensin II were reduced by PTH. The 
possibility that chronic effects are different cannot be 
ruled out.
Section 2 - Intracellular calcium in essential hypertension
4.2.1. The importance of adequate matching for age and 
body weight
In man, most studies on free calcium concentrations in 
cells have been carried out in platelets, cells that share 
with smooth muscle a calcium-dependent-contraction-coupling 
mechanism (106). Compared with some studies in primary hyper­
tension the differences in free calcium concentration 
observed were quite small. The results were similar to Lenz 
et al (118) who showed overlap between values in normotensive 
and hypertensive subjects, and only a small difference 
between the groups. In contrast to earlier studies 
(105,109,1 1 6,1 1 9), in the present series patients were well 
matched for age and body weight. The weak correlation between 
weight and [Ca^+]i was not significant but weight reduction 
in obese hypertensives seems to reduce platelet free calcium 
concentrations (320). It is unlikely that predominance of men 
in the hypertensive group affected the results; there was no 
difference in [Ca^+]i between men and women in the control 
group and the absence of sex difference has been confirmed by
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others (105,109). Degree of hypertension may be another 
relevant factor, although there were no obvious differences 
in pressure levels between current study and previous reports 
and indeed many of the hypertensives had evidence of left 
ventricular hypertrophy.
4.2.2. The relationship between platelet [Ca^+3i and blood 
pressure
A very close correlation between cytosolic free calcium 
concentration and diastolic blood pressure (r=0.9) was shown 
by Erne et al (105). Subsequent studies have shown weaker 
correlations (116,118,321) or lack of correlation (119). 
There was no correlation between [Ca^+]i and blood pressure 
or left ventricular mass in my series of patients. The 
current study included only patients with mild to moderate 
essential hypertension (WHO grade I and II). The first report 
(105) which showed the closest correlation between [Ca^+]i 
and blood pressure, was also the only one which included some 
hypertensive emergencies. This subset of patients seems to 
have been too small to have affected the overall results, but 
increased platelet turnover and thrombocytopenia is frequent 
in malignant hypertension (120). It is not known if intra­
cellular free calcium in platelets is related to the age of 
the cell.
Pritchard et al (321) demonstrated a positive 
correlation between [Ca^+]i and mean arterial pressure in a 
group of 18 subjects who were either normotensive or had mild 
to moderate essential hypertension. The majority of patients 
studied by Pritchard et al (321) were on long-term blood 
pressure lowering treatment and the treatment had only been
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withdrawn for a minimum of two weeks before sampling. The 
same practice of grouping together results of patients with 
untreated essential hypertension, and patients in whom the 
treatment had been discontinued for a limited period of time, 
has been used by other investigators (105,109,116,119). It 
must be doubtful if withdrawal of treatment for only two 
weeks is sufficient to allow the full reemergence of high 
blood pressure. I have included only newly diagnosed, 
untreated patients and this may contribute to differences in 
the results.
In common with other studies (105,109,321), I found 
significant positive correlation between changes in [Ca^+]i 
and reductions in systolic pressure during treatment. The 
number of subjects studied, however, was small and it was 
necessary to combine patients treated with different classes 
of drugs to obtain this result. It has been shown before that 
[Ca^+]i lowering effects are independent of the class of 
antihypertensive drugs used. Similar results have been 
obtained for calcium-channel blockers (105,109), beta-adreno- 
receptor blockers (105), thiazide diuretics (105) and angio­
tensin converting enzyme inhibitors (109). In both studies 
platelet free calcium decreased in parallel with blood 
pressure and the drugs examined appeared equipotent in this 
respect (105,109). Despite one report (146), which showed a 
lack of correlation between changes in [Ca^+]i and changes of 
blood pressure during treatment, most studies are consistent 
with the hypothesis that changes in platelet [Ca^+ ]i are 
related to changes in blood pressure.
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4.2.3. Methodological aspects
Various groups have used different methods to isolate 
platelets and the possibility that this could influence the 
measurements of cell calcium should be considered. I prepared 
platelets by centrifugation instead of gel filtration because 
preliminary experiments showed that intracellular calcium 
assay is only stable for two hours. After this period values 
tend to increase, perhaps due to leakage of the dye. 
Nevertheless, differences in [Ca^+]i have been demonstrated 
previously using platelets prepared by centrifugation (116). 
It seems unlikely that methodological reasons could explain 
the lack of difference in platelet calcium levels between 
normotensive and hypertensive subjects.
4.2.4. Mechanisms involved in [Ca^*ji reponse to arginine 
vasopressin (AVP)
Interest in calcium in platelets has extended to studies 
of mechanisms that control free calcium levels. It has been 
postulated that Ca^+ enters *the cell through two separate 
types of excitable channels: receptor-operated and voltage-
dependent calcium channels (as described in 1.2.2. and Figure 
1). In platelets there is some evidence suggesting the 
presence of voltage-dependent channels (56), although this 
has been questioned recently (324). Zschauer et al have 
demonstrated channels with the expected properties of 
receptor-operated calcium channels in thrombin-activated 
cells (325). The Ca^+ leak which causes the passive inward 
diffusion of Ca^+ in relaxed vascular smooth muscle has not 
yet been identified in platelets.
After platelet activation the increase in [Ca^+ ]i is
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mediated by calcium influx and release of calcium from 
intracellular stores (56 ,95 ,1 1 9,322). A large amount of 
calcium is bound to or stored in the dense tubular system, 
plasma membrane and mitochondria. AVP, like other agonists, 
induces the release of calcium from the dense tubular system 
and this is probably mediated by hydrolysis of phosphatidyl 
inositols (56,322). The relative contributions to increases 
of [Ca^+]i from internal stores compared with influx vary 
between different cell types and agonists. Responses of 
[Ca^+]i to AVP have been studied previously, but only in 
platelets from normal subjects (322). The receptor for AVP on 
platelets is of the V-j type, and similar to the receptor 
present on vascular smooth muscle (323).
The magnitude of the [Ca^+]i increase in response to AVP 
in the presence of 1 mmol/ 1 extracellular calcium was similar 
to that observed by Hallam et al (322). In the absence of 
extracellular calcium the increase was much smaller, which 
suggests that the increase in [Ca^+]i after AVP is largely 
dependent on calcium influx from the extracellular space. The 
difference between platelets from hypertensive and control 
subjects was also in this extracellular component, although 
the sensitivity of the assay may have limited ability to 
detect differences in the much smaller changes recorded in 
the presence of a calcium chelator. It has been mentioned 
previously (1.3.2.) that the . extra calcium buffering 
introduced by Quin 2 alters the pattern of evoked changes in 
[Ca^+]i (94,98,322). This may lead to an underestimation of 
the contribution from intracellular stores after agonist 
treatment (96,322). However, the intracellular calcium
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concentration has been reported to be independent of the 
intracellular Quin 2 concentration when measured in the range 
0.5-5 mmol/1 (94). Previous studies which employed identical 
loading conditions found that the mean concentrations of Quin 
2 in platelets were 1-4 mmol/1 and 1-2.8 mmol/1, 
respectively, with no differences between cells from patients 
and controls (105,109).
It is possible that Ca^+ influx is important in 
replenishing intracellular stores that have been discharged 
by inositol trisphosphate thereby maintaining the initial 
calcium response, perhaps by Ca^+ activation of non-selective 
cation channels in plasma membrane (326). The evidence 
presented makes it unlikely that platelet calcium 
abnormalities in hypertension are caused by overactivity of 
the receptor linked phosphatidyl inositol system and its link 
with calcium release or entry into the cells. The results 
with AVP tend to be opposite to the findings of a previous 
study which used thrombin as an agonist (119). It is not 
clear if this difference reflects receptor or post-receptor 
mechanisms. Basal plasma AVP concentrations in patients with 
essential hypertension have been variously reported to be 
either slightly higher ( 327) or lower ( 328) than in 
normotensive control subjects. Inaba et al (329). found an 
increased density of AVP receptors on platelets from 
hypertensive patients. Intrinsic differences in AVP receptor 
density and affinity or downregulation in response to high 
circulating levels of vasopressin cannot be excluded. It 
might also be relevant that Bukoski et al (143) demonstrated 
depressed [Ca^+]i transients in response to noradrenaline in
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mesenteric resistance vessels of the SHR as compared to WKY. 
There have been(no comparable studies in human resistance 
vessels.
Intracellular calcium homeostasis is maintained by the 
enzyme Ca^+-ATPase which is activated by calmodulin (65,66). 
Enzyme activity in platelets from hypertensive subjects seems 
to be altered, differences have been described in both total 
enzyme capacity and the calmodulin stimulated component. The 
second postulated calcium efflux system, Na+/Ca^+ exchanger, 
is probably not present in platelets because inhibition of 
Na+/K+ ATPase with ouabain does not ca.use changes in basal or 
stimulated [Ca^+]i (119).
4.2.5. The relationship between abnormal platelet function 
and possible abnormalities in stimulus-response 
coupling pathways in essential hypertension
Platelets have receptors for many different agonists 
including adrenaline, noradrenaline, serotonin, vasopressin 
and thrombin (331). Depending on the type of receptor, 
stimulation either triggers changes in cAMP or promotes 
formation of inositol trisphosphate (IP3 ) and diacylglycerol. 
Increased platelet calcium and diacylglycerol concentrations 
precipitate shape change, secretion and aggregation 
(331,332).
Aggregatory responses of platelets from hypertensive 
patients have been studied extensively and sometimes with 
conflicting results. Three out of eight studies found an 
increased aggregatory response to adenosine diphosphate (ADP) 
and one to noradrenaline (333-336). From a review by Nyrop
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and Zweifler (337), it appeared that severity of hypertension 
was an important variable. Differences in aggregation were no 
longer apparent when maan arterial pressure was reduced below 
120 mmHg with antihypertensive drug treatment (334,335). 
Abnormalities of platelet aggregation in hypertension may be 
a consequence of the vascular changes. I did not examine 
platelet aggregation but recent experiments from our 
laboratory (data not shown) suggest that changes in platelet 
calcium run parallel to changes in aggregatory responses. 
Since an increase in free calcium concentration is a 
necessary part of the process of activation, the higher 
[Ca^+]i concentrations in some studies may even reflect 
changes that occurred after blood sampling as a result of an 
enhanced tendency to activation and aggregation. The validity 
of the platelet as a model for the vascular smooth muscle 
cell is not yet firmly established.
Section 3 - Hypertension and primary hyperparathyroidism - an 
association?
4.3.1. Hyperparathyroidism as a long-term complication of 
the urinary calcium leak in essential hypertension 
Increased parathyroid gland function is probably one of 
the most frequent endocrine disorders associated with hyper­
tension. Primary hyperparathyroidism is said to be eight to 
ten times more frequent in patients with essential hyper­
tension than in the general population (212,217). In 
addition, it has been reported that thiazide diuretics cause . 
overt hypercalcaemia in a subgroup of hypertensive patients 
(213), a hypercalcaemic effect that may be related to the
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level of endogenous parathyroid hormone activity (313). 
McCarron et al (11) have even postulated that hyperpara­
thyroidism might be a consequence of the ren^l calcium leak 
in essential hypertension.
4.3.2. The prevalence of hypertension in primary hyper­
parathyroidism
In previous studies the prevalence of hypertension in 
primary hyperparathyroidism has been variously estimated 
between 10 and 70% (34,43,45,21 2,21 3). These figures must be 
viewed cautiously because the studies were retrospective and 
used different diagnostic criteria for hypertension. In the 
present small series of patients who were examined pros- 
pectively I found that five out of 23 patients (22%) had high 
blood pressure. This is similar to a recent study from 
Newcastle (195) where eight out of 24 patients were hyper­
tensive. I used the Hawksley random zero sphygmomanometer 
which eliminates some of the observer bias that may affect 
measurements with the ordinary mercury instrument.
4.3.3. Does surgical cure of hyperparathyroidism also cure 
hypertens ion?
As in several other studies, parathyroid surgery did not 
lower blood pressure (44,195,222,225,226). This finding must 
be interpreted in the context of the knowledge that 
correction of a secondary cause of hypertension often lowers 
blood pressure but does not always normalize it (338). In the 
present series, four out of 23 patients had a family history 
of high blood pressure in at least one first degree relative.
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Richards et al (222) found that three of six patients with 
high blood pressure and hyperparathyroidism had a positive 
family history of hypertension. The number of patients 
studied may be too small for definitive comments, but it 
appears that a subgroup of patients with high blood pressure 
and hyperparathyroidism may have coincidental essential 
hypertension.
In a meta-analysis Daniels and Goodman (34) have found 
that blood pressure returned to normal in 28% of patients. 
This subgroup may represent true hyperparathyroid-induced 
hypertension.
Section 4 - Why is [Ca^+]i lower in patients with primary 
hyperparathyroidism than in matched control 
subjects?
4.4.1. Possible role of parathyroid hormone and cyclic AMP
PTH enhances entry of calcium into many tissues (157) 
and might be expected to have a direct vasoconstrictor 
action on vascular smooth muscle cells. However, PTH itself 
is a vasodilator, as discussed in detail in 1.5.3. (1 56,1 59- 
166). The relaxant effect of PTH in vascular smooth muscle is 
primarily mediated by cAMP which stimulates phosphorylation 
of myosin light-chain kinase and lowers [Ca^+ ]i levels 
(167,169). Elevated serum concentrations of parathyroid hor­
mone in hypertensive patients might tend to buffer the in­
creased peripheral vascular resistance caused directly by 
hypercalcaemia. Chronic excess of PTH could also result in 
lowering of [Ca^+]i in some tissues and the platelet may be 
an example of this.
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4.4.2. Membrane-stabilizing effect of high extracellular
calcium concentration
Another explanation for the cell calcium findings might 
be the "membrane-stabilizing effect" of high extracellular 
calcium concentrations (51,62,72,74). Increasing calcium 
concentration from 1.6 to 4.1 mmol/1 potentiates the con­
traction of helical strips of the rat tail artery to nor­
adrenaline (72). Jones and Hart (74) have shown that supra- 
physiological concentrations of calcium ions (2.5 and 5.0 
mmol/1) cause a reduction in the rate of potassium> turnover 
in the rat aorta and the same phenomenon has also been 
described in lymphocytes (73). Calcium probably decreases 
membrane permeability to monovalent ions, alters membrane 
potential and thereby changes membrane permeability to cal­
cium or release of membrane-bound ion into the cytosol. Such 
a process might lead to reductions in [Ca2+]i in platelets 
exposed to high extracellular calcium concentrations and may 
also reduce calcium influx in response to vasopressin.
It seems unlikely that the difference in [Ca2+]i concen­
trations between patients with primary hyperparathyroidism 
and matched control subjects was due to increased cellular 
calcium in subjects with essential hypertension for two 
reasons. Firstly, platelet calcium concentrations in the 
hyperparathyroid group tended to be lower than those in 
normotensive controls. Secondly, platelet [Ca2+]i concen­
trations were similar in patients with essential hypertension 
and control subjects (Study I).
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Section 5 - Renin-angiotensin-aldosterone system and
catecholamines in primary hyperparathyroidism
4.5.1. Renin and angiotensin II
Brinton et al (194) proposed that high plasma renin 
activity could be an important factor in the hypertension of 
hyperparathyroidism. I found similar plasma concentrations of 
renin and angiotensin II in patients with primary hyperpara­
thyroidism and control subjects and no changes after surgical 
treatment. Similar results were obtained by Salahudeen et al 
(195) and Ganguly et al (221) who also showed that the res­
ponsiveness of renin to stimulation was depressed in hyper­
parathyroid patients. These results have not been supported 
by Richards et al (222) who studied eight patients before and 
after parathyroid surgery and did record a small fall in 
plasma renin activity.
Plasma concentrations of aldosterone were similar in the 
hyperparathyroid group and control subjects and this again 
confirms earlier experience (195,221). The small but sig­
nificant increase in plasma aldosterone concentration after 
surgery may have resulted from release of a tonic inhibitory 
effect of hypercalcaemia (47,222). Sowers and Barrett (47) 
studied rats with hypercalcaemia of malignancy and showed 
diminished aldosterone responses to angiotensin II and 
potassium. An effect of calcium on the metabolic clearance of 
aldosterone has not been excluded (222). There was no con­
vincing evidence that renin, angiotensin II or aldosterone 
were responsible for the high blood pressure in hyperpara­
thyroidism.
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4.5.2. Catecholamines and hyperparathyroidism
Release of catecholamines is calcium-dependent (22). 
Although Vlachakis et al (220) reported higher concentrations 
of catecholamines and metabolites together with increased 
vascular reactivity to noradrenaline in patients with hyper­
parathyroidism, these findings were not replicated in-later 
studies (221,222). I found that plasma concentrations of 
adrenaline and noradrenaline were similar in patients with 
primary hyperparathyroidism and control subjects, and not 
affected by surgery. One patient (No 13, Table 5) had 
elevated plasma concentrations of noradrenaline and 
adrenaline at 12.4 nmol/1 and 4.1 nmol/1 respectively, the 
normal range for our laboratory being below 5 nmol/1 for 
noradrenaline and 1 nmol/1 for adrenaline. The possibility of 
phaeochromocytoma was raised but repeated measurements of 
plasma and urinary catecholamines have not confirmed this 
diagnosis. No reason for the isolated elevation of plasma 
levels of catecholamines was established.
4.5.3. The relationship between plasma renin concentration 
and atrial natriuretic peptide
Atrial natriuretic peptide (ANP) is released from the 
heart in response to increases in atrial distension (339). 
This mechanical stimulus is linked to hormone secretion by 
activation of second messengers, namely intracellular calcium 
and phosphoinositol system (340,341). Plasma ANP con­
centrations appear to be increased in some patients with 
essential hypertension (342) but measurements have not been 
reported in patients with primary hyperparathyroidism. I 
found that plasma ANP concentrations were similar in the
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hyperparathyroid group to levels in normotensive control 
subjects and controls matched for blood pressure.
Richards et al (343) showed that plasma ANP concen­
trations increased after sodium loading and were inversely 
correlated with plasma concentrations of renin. Although 
patients in the study were on free diet, there was a weak 
inverse relationship between plasma concentrations of renin 
and ANP in the hyperparathyroid group.
Section 6 - Left ventricular hypertrophy in primary hyper­
parathyroidism
It has been reported that mortality from cardiovascular 
causes is increased in patients with primary . hyperpara­
thyroidism (211). Increased blood pressure could explain the 
relationship but mortality could also be related to left 
ventricular hypertrophy which has been described in an 
earlier series of patients with hyperparathyroidism (302). 
The excess of left ventricular hypertrophy in my patients may 
be related to direct actions of parathyroid hormone and/or 
extracellular hypercalcaemia on cardiac myocytes. An effect 
of differences in duration of hypertension between the two 
groups cannot be excluded. There was a tendency of left 
ventricular mass index to fall six to twelve months after 
parathyroid surgery. The absence of any correlation between 
left ventricular mass index and systolic or diastolic 
pressure in the hyperparathyroid group compared to the blood 
pressure matched control group was perhaps significant. This 
raises questions about the role of factors other than blood 
pressure in the development of left ventricular hypertrophy
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of hyperparathyroidism. Parathyroid hormone and calcium are 
both candidates.
Left ventricular hypertrophy may be associated with an 
increased prevalence of complex ventricular arrhythmias and 
sudden cardiac death (269,273,274) but any link between 
primary hyperparathyroidism and these effects is speculative.
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CHAPTER 5 - FINAL CONCLUSIONS
Section 1 - Study I
The first study examined platelet free calcium in 
essential hypertension and the interrelationships between 
intracellular calcium, blood pressure, left ventricular mass, 
levels of renin, angiotensin II and catecholamines. The 
following conclusions were drawn:
#  Resting platelet free calcium concentrations were 
similar in 30 patients with essential hypertension and 
30 well-matched control subjects. Close matching for age 
and body weight may be relevant to this result.
# Vasopressin caused a transient increase in platelet free 
calcium concentration, an increase that was sig­
nificantly lower in the hypertensive group than the 
control subjects. In the absence of external calcium, 
vasopressin caused much smaller changes in cytosolic 
calcium, and there was then no difference between the 
responses of the two groups. Intracellular calcium in­
creases after AVP seem to depend mainly on influx.
£ In a subgroup of patients, in whom platelet calcium
concentrations were measured after treatment with 
verapamil or atenolol, the changes in systolic pressure 
were correlated with changes in cytosolic free calcium 
concentrations. These parallel changes of [Ca2+]i and 
blood pressure lend some support to the hypothesis that 
changes in the platelet reflect changes in vascular
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smooth muscle, but the platelet as a model for the 
vascular smooth muscle cell has not yet been validated.
•  In untreated patients with essential hypertension 
platelet free calcium was not correlated with blood 
pressure, left ventricular mass, activity of the renin- 
angiotensin system or plasma concentrations of 
catecholamines.
Section 2 - Study II
The second study examined the relationships between 
cellular calcium metabolism, blood pressure and left 
ventricular mass in a group of patients with primary hyper­
parathyroidism. Other determinants of blood pressure such as 
the renin-angiotensin system, catecholamines and atrial 
natriuretic peptide were also measured. In the patients who 
had surgical treatment by parathyroidectomy the same 
variables were measured again six to twelve months after 
surgery. The following conclusions were drawn:
•  Patients with relatively mild primary hyperpara­
thyroidism had significantly elevated blood pressures 
compared with age-matched controls and 2 2 % of patients 
were hypertensive (WHO grades I and II). Parathyroid 
surgery had no blood pressure-lowering effects and the 
relationship between the two conditions may be more 
complex than previously suspected.
•  Despite chronic - extracellular hypercalcaemia, 
intracellular free calcium concentrations and calcium 
transients in response to vasopressin were lower in
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patients with hyperparathyroidism than in controls 
matched for age, sex and blood pressure. There was an 
inverse relationship between platelet calcium and 
diastolic blood pressure in the hyperparathyroid group 
and free cytosolic calcium concentrations tended to 
increase after parathyroidectomy. It appears that high 
external calcium and/or parathyroid hormone may lower 
intracellular calcium in platelets, perhaps by an effect 
of calcium on membrane stability or by cAMP-dependent 
mechanisms activated by parathyroid hormone.
#  Left ventricular mass index was increased in the hyper­
parathyroid group as compared to control subjects 
matched for age, sex and blood pressure. Para­
thyroidectomy was associated with a small reduction of 
this index. There was therefore slightly more left 
ventricular hypertrophy than might be expected from 
blood pressure alone. This may reflect a direct action 
of calcium or PTH on cardiac myocytes.
#  Plasma concentrations of the components of the renin- 
angiotensin system, catecholamines and atrial 
natriuretic peptide were similar in hyperparathyroid 
patients and in two control groups. Parathyroidectomy 
was followed by a small but significant increase in
- plasma aldosterone concentration, other variables 
remained unchanged.
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